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ABBREVIATIONS AND ACRONYMS
ANRS National Agency for AIDS Research—France
ART Antiretroviral therapy
CD4 Cluster of differentiation 4
CM Case management
FSW Female sex workers
HIV Human immunodeficiency virus
HIVST HIV self-testing
HPTN HIV Prevention Trials Network
mITT Modified Intention to Treat 
MSM Men having sex with men
MSW Male sex workers
MOH Ministry of Health
PLHIV People living with HIV
PWID People who inject drugs
RCT Randomized controlled trial
SOC Standard of care
START Strategic Timing of Antiretroviral Treatment
SVS Sustained viral suppression
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USAID United States Agency for International Development
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EXECUTIVE SUMMARY
INTRODUCTION
UNAIDS has identified the goals that by 2030, 95 percent of all people living with HIV (PLHIV) will 
know their HIV status; 95 percent of all people with diagnosed HIV infection will receive sustained 
antiretroviral therapy (ART); and 95 percent of all people receiving ART will have viral suppression 
(UNAIDS 2014). A proposed strategy to achieve the 95-95-95 HIV treatment targets is through 
the rapid scale up of HIV treatment for all PLHIV, regardless of CD4 count or viral suppression 
(UNAIDS 2014). 
Senegal represents a country that has been successful in the HIV response through early focus 
on prevention and the scale up of ART for PLHIV (Meda et al. 1999). HIV prevalence among 
reproductive age adults is relatively low at 0.5 percent, though a systematic review completed 
by our team highlighted the disproportionate burden of HIV among key populations, with 19.0 
percent prevalence of HIV among female sex workers (FSWs) and 21.7 percent among men who 
have sex with men (MSM) (Papworth et al. 2013)]. Additionally, results from the HIV prevention 
2.0 study, conducted in collaboration with Enda Santé in Dakar, Thiès, and Mbour, reported a 39 
percent prevalence of HIV among trans women (Poteat 2017).
Senegal plans a rapid scale up of HIV treatment for all PLHIV, regardless of CD4 count or viral 
suppression. Results from HPTN 052,1 START,2 and Temprano3 studies demonstrated the 
clinical benefit of early treatment. However, limited data exist on how to achieve sustained viral 
suppression (SVS) in real world contexts where significant barriers to effective ART delivery, 
uptake, and adherence persist. Thus, understanding the effectiveness of interventions around 
early initiation of ART and optimized retention is important for the continued HIV response.
The purpose of this study is to develop and assess the feasibility, fidelity, and cost-effectiveness 
of a universal coverage of ART intervention among PLHIV who are not virally suppressed in 
Dakar and Ziguinchor, Senegal. Specifically, this study aims to: 1) compare the effectiveness and 
durability of standard of care (SOC) versus individual case management (CM) programs to achieve 
SVS among PLHIV in Senegal; 2) characterize the acceptability of HIV self-testing (HIVST) by 
people at risk of HIV infection in Senegal, and determine if the promotion of self-testing increases 
the number of newly diagnosed PLHIV in clinic settings; 3) determine the cost-effectiveness of 
the universal treatment approach using the CM intervention; and 4) characterize the acceptability 
of iris scanning as a biometric follow-up strategy to enhance the measurement of follow-up and 
retention of PLHIV receiving ART care.
1HPTN 052 study: https://www.hptn.org/research/studies/hptn052 
2START study: https://www.ninds.nih.gov/Disorders/Clinical-Trials/Strategic-Timing-Antiretroviral-Treatment 
3 Temprano study: https://clinicaltrials.gov/ct2/show/NCT00495651 
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METHODS
This study used an individual-level randomized controlled trial (RCT) to examine the impact of 
CM on viral suppression of PLHIV at 12 months compared to the SOC. A total of 596 participants 
were enrolled into the study, with 298 in both Dakar and Ziguinchor. To characterize self-testing 
and iris scanning, the number of PLHIV testing at specific referral clinics was compared before 
and after the implementation of self-testing, and implementation outcomes were assessed on the 
use of self-testing and iris scanning including uptake, routinization, acceptability, and long-term 
feasibility. The results of this study are intended to provide clearly articulated implementation 
plans for the use of HIVST approaches, CM interventions to improve retention in ART, and iris 
scanning to support measurement of retention in ART programs in Senegal. 
Study sites included two government HIV treatment facilities in Ziguinchor and two in Dakar, due 
to the partnership between this study and the Senegal Ministry of Health (MOH). Participant 
enrollment into the study took place at the study sites, and study arms (SOC or CM) were 
assigned through individual randomization at the clinic level. Facility-level data were used to 
assess each HIV facility and determine the study site, in collaboration with Senegal MOH. The 
Government of Senegal made early treatment available for all PLHIV enrolled during this study, 
and the HIV self-test kits were procured through Project SOAR. However, the study supported 
the implementation of the CM intervention and the use of iris scanning as a biometric follow-
up system for all enrolled in the study and the modification of the HIV self-testing kits based on 
feedback from consultations as to the appropriate design.
The study lasted 15 months from the time of the first participant enrollment to the last study 
visit. Each participant was part of the study for a maximum of 12 months. The cohort follow-up 
involved five study visits, lasting up to two hours each. 
HIV self-testing
HIVST kits were distributed as an intervention, with the aim of increasing the number of new 
HIV diagnoses to drive testing yield in both arms of the study. The HIVST kits included an oral 
swab test stick and tube with solution, step-by-step instructions and HIV information booklets in 
French and Wolof, referral to an HIV health facility for confirmatory testing, and the study contact 
information.
in this phase of the study 1,839 HIVST kits were distributed. Of these, 1,149 individuals 
participated in the pre-test survey and from those, 817 individuals participated in the post-test 
survey. HIVST kit distribution took place during the first 6 months of enrollment into the study. 
HIVST kits were distributed to potential participants visiting the study sites and through partner 
organizations currently working with populations at increased risk for HIV. This study leveraged 
several methods for HIVST kit distribution including 1) supervised distribution, whereby HIVST 
kit-trained distributors provided pre-test instructions; 2) unsupervised distribution, relying on the 
written instructions and referral included in the self-test kit, without any additional supportive 
guidance; 3) venue-based distribution, implemented by partner organizations in sex work venues, 
bars, and nightclubs; and 4) network-based distribution, implemented by peer educators who 
received and distributed the HIVST to two other individuals using unsupervised distribution. 
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Individuals receiving the HIVST were asked if they wished to participate in a pre-and post-test 
survey. The survey collected information about demographic characteristics, socioeconomic 
status, behavioral characteristics, health and HIV treatment history, and HIV acquisition risks. 
It also collected information on HIV testing history, specifically recent use of HIVST. The post-
test survey asked about implementation outcomes including the use of HIVST, HIVST results, 
acceptability, routinization, feasibility, and adoption. 
Case management intervention
This study assessed the Senegalese SOC and CM, with the purpose of comparing the 
effectiveness and durability in achieving SVS among PLHIV in Senegal. The SOC for treatment 
support for PLHIV in Senegal included facility-based ART initiation and follow-up systems 
leveraging appointment books, though without active reminders. The CM intervention was a multi-
step process to coordinate care and provide a family-like support system for PLHIV. Peer health 
navigators received a capacity building training in case management at each study site as part of 
the intervention. The training's goal was to reinforce their health navigation capacities, train them 
in case management, and provide them with the tools to adequately fulfill their role as new case 
managers. 
After assignment of a case manager to each study participant, the approach had five key 
components: 1) initial meeting between person living with HIV and case manager; 2) follow-up 
meeting between case manager and participant; 3) biweekly automatic text messages sent to 
participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between 
case manager and participant every six months. 
Recruitment and participant enrollment into the RCT took place at the health facility assigned as 
a study site. Self-testing kits were used to increase the number of potential study participants. 
Study participants were not excluded if not recruited through the self-testing kits. Trained health 
facility staff provided potential study participants with information and obtained informed consent 
from participants. Eligible participants completed a structured 1-hour interviewer-administered 
questionnaire, which served as the baseline assessment. Participants assigned to the CM 
intervention received SOC treatment CM support. All study visits took place at the study site and 
lasted approximately two hours each.
Baseline assessment of study participants included a questionnaire and biological testing. The 
baseline questionnaire assessed demographic characteristics, socioeconomic status, mobility 
and migration history, behavioral characteristics, health and HIV treatment history, and HIV 
acquisition risks. The baseline assessment also collected information on HIV testing history, 
specifically recent use of HIVST. For those who received an HIVST kit, there was significant 
attention placed on the measurement of implementation outcomes including the use of HIVST, 
HIVST results, acceptability, routinization, feasibility, and adoption. Follow-up involved visits 
at 3, 6, 9, and 12 months after the first visit. Questionnaires were administered at each visit. 
Questionnaires assessing behavioral characteristics, mental health, social support, and ART 
treatment adherence were administered at 6 months and 12 months. Abbreviated questionnaires 
were re-administered at three and nine months and assessed implementation outcomes 
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associated with HIVST and CM; the use of iris for tracking and engagement in ART services; and 
enacted, perceived, and intersectional stigma.
The data to assess the cost-effectiveness of the use of CM intervention were collected as part 
of this study. From the participant perspective, a standardized questionnaire based on the 
WHO’s “Tool to Estimate Patients’ Costs” was used to assess the cost to individuals in accessing 
and maintaining participation in CM. We also used two instruments: the brief version of the 
WHO Quality of Life instrument (WHOQOL-BREF) and the EQ-5D to assess participants’ quality 
of life and health utility, respectively. The use of these two instruments enabled us to capture 
not only the indirect effects of such interventions on reducing HIV transmission, but also their 
direct effects on individuals’ quality of life. Cost-related data were collected from the healthcare 
perspective as well, including (a) hiring and training of case managers; (b) monthly costs of 
preparing and delivering support through case managers; and (c) program implementation and 
oversight, including physical resources (e.g., office space), human resources, and overhead. 
Biometric follow-up system
The biometric follow-up system intervention was conducted among participants in the CM 
and SOC cohorts. Iris scanning was used as a way to track participants and was focused on 
supporting evaluation of retention in ART. Preliminarily, the iris scanners and a laptop were placed 
in the study sites in Dakar and Ziguinchor, and all participants who initiated ART at these facilities 
had an iris scan as a means of registering into the study. The iRespond system was used for this 
study, including biometric scanners manufactured by CMITech. The image of the iris was not 
stored but rather was converted into a 12-digit numerical code, which was stored in the electronic 
health record. The iris was scanned at each study visit to identify the participant, and link the 
information obtained from the study visit to the previous information collected.
Iris scanning was a mandatory component for enrollment into the study, and therefore if a 
participant did not consent to the use of iris scanning, they were not enrolled into the study. 
Sample size and all associated calculations were the same for the biometric follow-up system as 
for the CM vs. SOC portions of the study.
RESULTS
HIV self-testing
From the 1,144 participants that completed the pre-test survey, 47 percent had never previously 
received an HIV test and were thus classified as first-time testers. Twenty-seven percent had 
had some history of HIV testing but had not been tested within the last 12 months, and only 26 
percent had tested within the last 12 months. 
A large proportion, 56 percent, of those identifying as men were first-time HIV testers. Women, 
meanwhile, were first-time testers in 39 percent of the cases. After adjustment, men were found 
to have 2.71 (2.08, 3.52) increased odds of being a first-time tester as compared to females. 
Thirty seven percent of participants who identified as key populations (male sex workers, men 
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who have sex with men, people who inject drugs, or trans women), reported never having been 
administered an HIV test Among female sex workers, the proportion of first-time testers was 
lower at approximately 21 percent, and the proportion that had tested within the last 12 months 
was 52 percent. Almost 63 percent of young adults (aged 18-24) were found to have never been 
administered an HIV test. Those aged 25–30 years were meanwhile found to be first-time testers 
46 percent of the time, and those aged 31 and over were first-time testers 38 percent of the time. 
After an adjustment for region and sex, young adults had 2.84 (2.07, 3.90) increased odds of 
being a first-time tester when compared to participants aged 31 years and older. 
Among the 877 individuals who participated in the post-test survey two weeks post-distribution, 
94 percent reported having used the HIVST. Fifty-five percent of participants chose to use the 
test at the distribution site while 46 percent used it at home. Eighty-nine percent of participants 
reported that they had used the self-test kit within 2 days of the distribution date, but only 10 
percent of individuals reported having sought confirmatory testing. A vast majority of participants, 
95 percent, reported that they would recommend the HIVST kit to others. Overall, we found that 
use and acceptability of HIVST did not significantly differ between first-time testers and those with 
a previous testing history.
CM vs. SOC
The sample included 573 participants that were allocated to receive either standard of care 
(n=281) or the case management treatment (n=292). On average, participants were 36 years of 
age and the largest proportion (35%) had never attended school. Fifty-six percent of participants 
indicated that their sex at birth was female, and 57 percent identified as female at the time of 
the intervention. Among the SOC group, 21 percent of participants were sex workers while 24 
percent were MSM. The proportion of these key populations was slightly smaller among the CM 
group, where 16 percent of participants were sex workers and 21 percent were MSM. Forty-three 
percent of SOC participants were on treatment at the outset of the intervention while a majority, 
89 percent, had been newly diagnosed with HIV. In the CM group, 46 percent were on treatment 
and 85 percent were newly diagnosed. 
In healthcare settings, only 9 percent of participants shared having ever avoided seeking 
healthcare because of their positive HIV status. No participant reported feeling mistreated or 
having been denied services by healthcare workers. Among the CM participants, 9 percent 
reported fear of being in public places, and 2 percent of had been blackmailed compared 
to 6 percent that were blackmailed in the SOC arm. In this study, the results show that out 
of 112 MSM surveyed at baseline, only 9 felt comfortable enough to talk about their sexual 
orientation with their family or friends. A few MSM participants, 14 percent (n=16), were often 
afraid to attend health facilities for their care needs, because of risk of stigmatization. This was 
more common among patients followed in standard care (19%) than those followed in case 
management (9%). Social stigma is the phenomenon most felt among FSWs in this study. In 
addition to stigmatization, FSWs also reported being survivors of violence. This violence takes 
the form of physical assault (15%), fear of going to public places (9%), verbal harassment (12%), 
blackmail (18%), and assault or sexual violence (24%).
6  ■  Leveraging adaptive implementation strategies to achieve universal coverage of ART in Senegal
The percentage of SOC participants indicating they never used a condom for sex with their 
principal partners over the past 30 days decreased from 33 percent to 16 percent between the 
baseline and fifth visit. In the CM group, meanwhile, 28 percent initially indicated they never 
used a condom with their principal partners over the past 30 days. This number decreased to 10 
percent on the third visit and increased to 13 percent during the fifth visit.
Mental health was assessed using the Patient Health Questionnaire (PHQ-9). A score of 0–4 
suggests minimal or no depression, 5–9 mild depression, 10–14 moderate depression, 15–19 
moderately severe depression, and 20–27 severe depression. Between the first and fifth visit, the 
percentage of participants in the SOC arm with no depression increased from 64 percent to 87 
percent. This trend was consistent for participants experiencing mild depression; this proportion 
decreased from 24 percent to 11 percent. Similarly, those experiencing moderate levels of 
depression decreased from 9 percent to 0.6 percent during the third visit, but increased to 2 
percent during the fifth visit. Participants in the CM arm also displayed a decrease in the burden 
of depression between the first and fifth visit, with 65 percent of participants reporting no signs 
of depression at the first visit, 89 percent at the third visit, and a slight decrease to 84 percent 
at the fifth visit. At the first visit, 25 percent of participants in the CM arm experienced mild 
depression, 10 percent during the third visit, with a slight increase to 13 percent during the fifth 
visit. One percent of participants experienced moderately severe depression at the first visit, and 
no signs at the third and fifth visit. 
The proportion of participants in the SOC arm who reported a very poor ability to take ART 
medication between the third and fifth visits increased from 0.6 percent to 3 percent. Those 
with a good ability to take ART medication averaged 37 percent, and those with an excellent 
ability decreased from 26 percent to 20 percent. In the CM arm, participants with a good ability 
increased from 26 percent to 27 percent, and those with an excellent ability similarly decreased 
from 36 percent during the third visit to 29 percent during the fifth visit.
When read the statement “I was satisfied with the case manager,” 33 percent of SOC participants 
responded that they strongly agreed and 60 percent that they agreed. In the CM group the 
numbers were 30 percent and 65 percent respectively. Ninety-five percent of SOC participants 
indicated that they either strongly agreed or agreed that they found the meetings with the case 
manager to be helpful, while 99 percent of CM participants had the same response. In both 
groups, a vast majority indicated that they either strongly agreed or agreed that they felt better 
equipped after the intervention (95% in the SOC group and 98% in the CM group). In regard to 
expanding the program to all PLHIV, 95 percent of the SOC group and 98 percent of the CM group 
either strongly agreed or agreed that meetings with a case manager should be made available 
to all PLHIV. The preference of patients wishing to continue to receive the support of case 
managers as was provided in the study, if available, is important. Eighty three percent of patients 
in standard care and 91 percent in case management would choose to continue with the support 
they received.
Viral suppression did not differ significantly according to randomized group at 6 months (77% 
in the SOC arm and 77% in the CM arm) and 12 months (74% in the SOC arm and 70% in the 
CM arm). There was no evidence of the durability of viral load suppression among 6-month 
responders continuing in both arms. While no participant characteristics were statistically 
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significantly associated with viral suppression at the 6-month visit, at the 12-month visit, 
moderate depression was negatively associated with viral suppression. 
Iris scanning
Responses obtained from patients at inclusion in visit 3 and 5 show that more than 83 percent of 
the patients found the iris scanner comfortable or very comfortable to use, with a slight difference 
depending on the visit. In fact, the percentage of patients who thought it was acceptable or very 
acceptable increased from 46 percent at baseline to 94 percent at visit 5. Within the framework 
of this study, the evaluation of the acceptability of using iris scanners as a strategy for identifying 
and monitoring patients living with HIV was done at all visits. At baseline (n=49), visit 3 (n=115), 
and visit 5 (n=171), more than 90 percent of patients felt that the iris scanner was acceptable or 
very acceptable in their identification and follow-up. This rate of acceptability in identification for 
the CM participants is slightly higher at M64 (98%), then at M12 (93%) than at M0 (87%). Patient 
satisfaction with the use of the iris scanner was very high. More than 90 percent of them reported 
being satisfied or very satisfied with the use of the device. Those who were very satisfied were 
more numerous at M0 (25%), than at M6 (11%) and M12 (18%). As for acceptability of the iris 
scanner, more than 94 percent agreed to use it in the future.
CONCLUSION
This study was the first HIVST pilot study conducted in Senegal describing HIVST acceptability 
and feasibility for HIV testing in key populations. It was successful in reaching first-time testers, 
including a large proportion of men and young people, and people who did not traditionally access 
HIV services. These results have made it possible to define strategies for distributing HIVST to the 
populations most affected by HIV, including key populations, for various projects currently being 
implemented in Senegal and West Africa.
The intervention, through capacity building of case managers, aimed to improve patients' 
adherence to treatment, and hence viral load results. Although the study did not find a significant 
difference in the viral load results between the two arms at the end of the study, an improvement 
in viral load results was observed over time. Case managers remain essential in the follow-up and 
retention in care of PLHIV. Further analyses will be conducted to elucidate the factors associated 
with these outcomes.
The use of unique identifier codes for measuring patient retention remains essential in the 
context of HIV programs. Participants reported feeling comfortable using the iris scanner. It 
represents an alternative strategy in a context where key populations are hidden and mobile, 
allowing for better monitoring and also avoiding duplication of codes.
4M=Month 
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RECOMMENDATIONS
The results from the study demonstrate that HIVST provides a complementary approach to reach 
populations who may face barriers to engagement with existing and routine HIV testing services. 
These data suggest the potential impact that HIVST could have in complementing existing HIV 
testing services by reaching a diverse group of first-time HIV-testers as well as those who have not 
tested recently in Senegal. Preliminary results from this study guided the development of national 
HIVST guidelines. Senegal has moved forward with recommending it as an additional approach to 
testing priority populations, including key populations, based on the study's preliminary results 
Among participants with a reactive HIVST, 58 percent went for confirmatory testing, and among 
those with an invalid test result, none went for follow-up testing. Follow-up in this context is a 
challenge. Implementation of HIVST should include specific strategies for confirmatory testing, 
thus ensuring effective linkage to care for newly HIV diagnosed individuals. 
Patient monitoring in Senegal remains a challenge for the national ART program, especially during 
the agricultural season, with patients absent over a long period. Study participant follow-up was 
equally impacted, with participants not attending all study visits. Specific strategies to overcome 
this barrier could include strengthening of regional and cross-border referral and counter-referral 
systems between health facilities.
Case managers play a crucial role in participants' retention in care and sustained adherence to 
ART by providing navigational services and accompanying the patient throughout their journey. 
Continuous capacity building is recommended, with an emphasis on support, therapeutic 
education of the patient, and provision of adequate job tools. 
While ART medication is provided free of charge in Senegal, the sites experienced stockouts of 
ART medication and viral load reagents, causing delays in treatment initiation and interruption. 
This component should be evaluated before any implementation of a Test and Start strategy.
Iris scanners represent an acceptable technology for PLHIV identification and follow-up in settings 
such as Senegal. Most participants reported being comfortable using them. Implementation 
should also include adequate training of staff on usage and development of appropriate 
communication before use with patients. 
Participants reported having felt stigma from the community due to their HIV status. 
Communication strategies addressing HIV-related stigma, specifically through renewed 
investments in advocacy campaigns targeting opinion leaders, including the media and religious 
leaders, are needed to act on the social environment.
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BACKGROUND AND RATIONALE
UNAIDS has identified the goals that by 2030, 95 percent of all people living with HIV (PLHIV) will 
know their HIV status; 95 percent of all people with diagnosed HIV infection will receive sustained 
ART; and 95 percent of all people receiving antiretroviral therapy (ART) will have viral suppression 
(UNAIDS 2014). A proposed strategy to achieve the 95-95-95 goals is through the rapid scale up 
of HIV treatment for all PLHIV, regardless of CD4 count or viral suppression (UNAIDS 2014). In 
Senegal, the government has initiated a process to collect different types of feasibility data that 
would inform an eventual national guideline adopting test and treat for all those living with HIV 
as a means of improving clinical outcomes and, ultimately, addressing the HIV epidemic. Since 
this approach has yet to be implemented in the Senegalese context, the data generated by this 
study would inform the utility of this approach in the local Senegalese context as well as guide 
implementation.
Senegal represents a country that has been successful in the HIV response through early focus 
on prevention and the scale up of ART for PLHIV (Meda et al. 1999). HIV prevalence among 
reproductive age adults is relatively low at 0.5 percent, though a systematic review completed 
by our team highlighted the disproportionate burden of HIV among key populations, with 19 
percent prevalence of HIV among female sex workers (FSWs) and 22 percent among men who 
have sex with men (MSM) (Papworth et al. 2013). In an effort to continue mitigation of the HIV 
epidemic, the government of Senegal has communicated plans to USAID as well as proposed 
investigators here for a rapid scale up of HIV treatment for all PLHIV, regardless of CD4 count or 
viral suppression.
At the 2015 IAS meeting in Vancouver, updated HPTN 052 data demonstrated that the preventive 
benefit of treatment in serodiscordant couples is maintained over time with sustained viral 
suppression (SVS), with 93 percent benefit for genetically linked transmissions. However, when 
evaluating all transmissions, including those acquired from sexual partners outside of the primary 
partnership, the efficacy was reduced to 67 percent (HPTN 2015). Data from the Strategic Timing 
of Antiretroviral Treatment (START) study also demonstrated the clinical benefit of early treatment 
for those living with HIV (NIH 2015). Lastly, the ANRS Temprano study demonstrated the same 
benefits of early treatment with tuberculosis prophylaxis for PLHIV in Cote d’Ivoire (Danel et al. 
2015). While these three studies reinforce the importance of treatment, there remain limited data 
on how to achieve SVS in the real world, with significant barriers to effective ART delivery, uptake, 
and adherence. In the context of the HIV epidemic in Senegal, with a disproportionate burden 
of HIV among key populations, understanding the effectiveness of interventions around early 
initiation of ART and optimized retention is important for the continued HIV response.
HIV SELF-TESTING
HIV self-testing (HIVST) is emerging as an important tool to promote HIV screening and, 
potentially, to increase frequency of HIV testing in at-risk populations for whom more frequent 
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testing is recommended (WHO 2014). In many places, there is stigma associated with seeking 
HIV testing. For key populations, in particular, requesting an HIV test regularly may be perceived 
by clients or healthcare providers as disclosing a stigmatized behavioral risk. Self-testing can 
potentially overcome these barriers to HIV testing uptake by placing the locus of control of testing 
on the individual, increasing confidentiality, and allowing members of stigmatized groups to test 
in settings with privacy, safety, and dignity. Self-testing has become possible as HIV rapid tests 
have grown more sensitive, and devices have become less complex, enabling testing in field 
settings. There are a number of possible device options that could be used in an HIV self-testing 
program. While the majority of the work has taken place in higher income settings (Sharma et 
al. 2014), emerging work from low- and middle-income countries has shown similar acceptability 
and comprehension of the materials, supporting the use of self-testing. Consequently, there 
are HIVST products that were developed by companies in France (Autotest VIH, AAZ), United 
Kingdom (Biosure HIV Self-Test), and in the United States (OraQuick In-Home HIV Test, OraSure 
Technologies). There are also specific policies for licensure and registration in the United States 
and United Kingdom, with more countries having policies in place explicitly allowing HIVST 
including Australia, France, Hong Kong, Kenya, and South Africa. Far more countries have 
policies under development including several sub-Saharan African countries, though there are 
no West and Central African countries in this list yet. Several interesting analyses have taken 
place, including the “Acceptability and feasibility of a novel approach to promote HIV testing in 
sexual and social networks using HIV self-tests,” presented by Dr. Harsha Thirumurthy at the 
IAS 2015 Meeting in Vancouver, which demonstrated good uptake of self-testing and the ability 
to distribute these tests through social networks. This approach leveraged the semi-restricted 
model of distribution, though having broader open access is also an accepted approach, as 
is more clinically restricted approaches whereby HIVST would take place in health facilities. 
In studies in Malawi, the highest uptake of HIVST was among adolescents, with high levels of 
return of questionnaires distributed, and self-testers included a large number of first time HIV 
testers (Figueroa et al. 2015). While HIVST had not been formally promoted by the Senegalese 
government when the study was introduced, the Ministry of Health (MOH) was interested 
in evaluating the potential of this approach in this study setting to boost numbers of newly 
diagnosed people.
CASE MANAGEMENT VS. STANDARD OF CARE
Case management (CM) is a multi-step process to coordinate care and provide a family-like 
support system for PLHIV. This approach involves the assignment of a case manager to a patient 
with the goal of providing health care and supportive services navigation, adherence counseling, 
and tailored support for care engagement and treatment adherence. CM approaches build on 
cognitive behavioral theory and help address barriers to treatment uptake, adherence, and 
retention by working with individuals to set treatment goals, build treatment literacy and self-
efficacy to execute treatment plans, and provide social and logistics support to patients to achieve 
their goals (Wall et al. 2015). CM approaches have been successfully employed by nurses, social 
workers, and HIV counselors for individuals living with HIV (Farley et al. 2014). In South Africa, 
CM interventions for different populations, including those co-infected with HIV and tuberculosis, 
pregnant women living with HIV, and FSWs at risk for and living with HIV, have been broadly used 
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(Schwartz et al. 2105; Clouse et al. 2015). CM approaches build on long experience of using 
ancillary health workers to support medication adherence among those living with HIV (Kenya 
et al. 2014; Chamie et al. 2014). The CM approach proposed in this study will adapt the MyLife, 
MyChoices, MyCare, and MyHealth model being used by PI-Baral and others in a HIV Prevention 
Trials Network study among MSM (HPTN 078) (Farley et al. 2014).
BIOMETRIC FOLLOW-UP SYSTEM
Unique identifier codes (UIC) are an essential component of measuring retention in health 
services. National health identifiers are often used, but are often challenged by limited uptake 
at the local clinic level. Biometric measures, such as digit fingerprinting, have been used in a 
variety of settings including the Sex Work Outreach Program in Kenya as well as more recently 
for a cohort of sex workers in Zambia. Fingerprint-based biometrics have also been used in HIV 
programming in Uganda and in the US (Chamie et al. 2014; Cohen et al. 2012). In all cases, the 
acceptability has been relatively high among those at high risk for HIV. However, there have been 
challenges in the implementation of digit fingerprinting, as well as legitimate privacy concerns. 
In 2012, there were discussions about the use of digit fingerprinting for a study in Senegal, and 
at that point it was deemed problematic. However, at that time, the studies were focused on HIV 
prevention, and UIC leveraging reproducible anonymous codes were deemed acceptable. Due to 
interest in assessing biometric measures, as well as the concerns around stigma relating to digit 
fingerprinting, iris scanning has been adopted for this study’s biometric measure. Iris scanning 
has been used in Guinea during the Ebola outbreak in 2015, in Burma with HIV patients through 
Population Services international, in Kenya related to HIV among key populations, and in Thailand 
in partnership with the MOH. Given the increasing focus on ART and the significant importance 
in measuring loss to follow-up in treatment studies, biometric UIC are an important component 
of the follow-up plan of this study. The discussions with the Senegalese MOH in 2015 highlighted 
enthusiasm about the use of biometric measures, and conversations with the MOH in 2016 
highlighted interest around iris scanning as a biometric follow-up system.
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OBJECTIVES AND STUDY AIMS
The overarching goal of this study is to assess the feasibility, fidelity, and cost-effectiveness of 
a universal coverage of ART intervention among individuals living with HIV who are not virally 
suppressed in Dakar and Ziguinchor, Senegal. 
 y Specific Aim 1: Characterize the acceptability of HIVST by people at risk of HIV infection 
in Senegal, and determine if the promotion of self-testing increases the number of newly 
diagnosed PLHIV in clinic settings.
 y Specific Aim 2: Compare the effectiveness and durability of the existing standard of care (SOC) 
in Senegal versus individual CM programs to achieve SVS among PLHIV in Senegal.
 y Specific Aim 3: Determine the cost-effectiveness of the universal treatment approach using the 
CM intervention.
 y Specific Aim 4: Characterize the acceptability of iris scanning as a biometric follow-up strategy 
to enhance the measurement of follow-up and retention of PLHIV receiving ART care.
STUDY OVERVIEW
This study was structured as a randomized controlled trial (RCT) that used an effectiveness-
implementation hybrid design to test the effectiveness and durability of CM interventions in 
achieving SVS among PLHIV who are not virally suppressed. CM vs. SOC approaches were 
assessed using an individual-level RCT of case management to improve viral suppression of 
those living with HIV at 12 months compared to the Senegal SOC. While viral suppression was a 
primary outcome of this intervention, significant attention was given to the collection of service 
and implementation outcomes to assess both the SOC and CM. The secondary aim of this study 
was to characterize acceptability of HIVST and iris scanning for the diagnosis and retention in ART 
among those living with HIV. 
Since test and treat has not yet been evaluated in the Senegalese context, the results of 
this study will improve the understanding of the effectiveness of this intervention and inform 
the roll out of this national strategy. These results are intended to provide clearly articulated 
implementation plans for the use of HIVST approaches in Senegal, CM interventions to improve 
retention in ART, and iris scanning to support measurement of retention in ART programs. We 
will provide details regarding who delivers the intervention, the setting of the intervention, 
the dose and frequency of the intervention, and outcomes of the intervention. Combining the 
primary outcome of SVS with additional implementation outcomes, including acceptability, 
fidelity, appropriateness, routinization, and sustainability, is an innovation in measuring the 
potential utility of this approach. The primary outcome of effectiveness here is a binary outcome 
of SVS. One innovation includes the integration of implementation research outcomes with 
the effectiveness outcome to interpret results in the context of how these data can inform 
real-world HIV programs. Thus, several well-established implementation measures, including 
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appropriateness, fidelity, sustainability, and implementation costs, will be measured during the 
course of the study (Procter et al. 2011).
Figure 1  Study overview
CONTEXT AND SITES
Study sites included two government HIV treatment facilities in Ziguinchor, and two in Dakar. 
Participant enrollment into the study took place at the study sites, and study arms (SOC or CM) 
were assigned through individual randomization at the clinic level. Notably, the HIV treatment 
facilities are existing government facilities, due to the partnership between this study and the 
Senegal MOH.
Monitoring and evaluation data collected by the Senegal MOH were shared with our team to 
help assess the current patient flow in the health facilities. The current number of patients living 
with HIV under care in government HIV facilities was approximately 5,583 in Dakar and 2,005 in 
Ziguinchor. Among new patients receiving HIV tests, 35 percent were men and 65 percent were 
women. The number of new positive HIV diagnoses was approximately 125 individuals per week 
in Senegal. There were seven HIV facilities in Dakar and two in Ziguinchor, which were assessed 
for study site selection. Facility-level data were used to assess each HIV facility and determine the 
study site, in collaboration with Senegal MOH.
The Government of Senegal made early treatment available for all PLHIV enrolled during this 
study, and the HIVST kits were procured through Project SOAR. However, the study supported 
14  ■  Leveraging adaptive implementation strategies to achieve universal coverage of ART in Senegal
the implementation of the CM intervention and the use of iris scanning as a biometric follow-
up system for all enrolled in the study and the modification of the HIV self-testing kits based on 
feedback from consultations as to the appropriate design.
AIM 1: HIV SELF-TESTING
Overview
HIVST kits were distributed as an intervention, with the aim of increasing the numbers of new 
HIV diagnoses to drive accrual into both arms of the study. Self-testing kits were distributed as 
a means of facilitating recruitment into the study by increasing the number of potential study 
participants visiting the study sites during the enrollment period. The approaches also utilized 
supervised or unsupervised distribution of the HIVST.
HIV self-test kits
The HIVST kits include:
1. Written, step-by-step instructions on the correct use of the self-test.
2. An oral swab test stick and tube with solution.
3. Information booklets on HIV and testing.
4. Educational information about the test.
5. Referral to an HIV health facility for confirmatory testing.
a. For those who test positive with the HIVST kits, the referral provided inside the kit will direct 
the individual to a study site in order to facilitate the linkage to ART.
b. Referral cards will either be a sticker or a small card containing the information for both 
study sites in the respective city.
6. A phone number is provided on the HIV self-test kit referral card. This is the phone number 
of the study coordinator, and the participants are encouraged to call this number with any 
questions or information for referrals.
The instructions included in the kit are provided in French and Wolof, and adapted to the 
Senegalese context. For those who test positive with the HIVST kits, the referral provided inside 
the kit directs the individual to a study site in order to facilitate the linkage to ART.
OraQuick HIV Self-Test Kits are used for the HIVST in this study. OraQuick is manufactured by 
Orasure Technologies, Inc (www.OraSure.com). Clinical studies have estimated that the sensitivity 
of the OraQuick In-Home HIV Test is 92 percent, meaning that 92 percent of the results will be 
positive when HIV is present. Clinical studies have also shown that OraQuick In-Home HIV Test 
has a specificity of 99.98 percent, representing the percentage of results that will be negative 
when HIV is not present. The United States Food and Drug Administration has issued a premarket 
approval for the Oraquick In-Home HIV test: http://www.fda.gov/BiologicsBloodVaccines/
BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/ucm311895.htm
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Participants and recruitment
This study focused on researching populations with a disproportionate burden of HIV and 
individuals who do not seek/agree to HIV testing in the health facilities. HIVST kits were 
distributed through partner organizations currently working with populations at increased risk for 
HIV. This includes associations and organizations working with MSM, FSWs, trans women, and 
people who inject drugs (PWID). The HIVST distribution was led by Enda Santé, an organization 
with extensive experience working in these communities.
In this phase of the study 1,839 HIVST kits were distributed. A total of 1,149 individuals 
participated in the pre-test survey, and from among those, 817 individuals participated in the 
post-test survey.
Inclusion criteria
 y 18 years of age or older
 y Mentally sound and capable of providing consent to participate
 y Agrees to complete HIV self-test
 y Speaks either French, Wolof, or both
 y Provided informed consent to participate in the survey
Exclusion criteria
 y Under 18 years of age
 y Demonstrates mental incapacity, under the influence of substances, or any other illness 
preventing comprehension of the study procedures and informed consent
 y Does not agree to complete HIV self-test
 y Has not provided informed consent to participate in the study
Recruitment process
HIVST kits were distributed as an intervention, with the aim of increasing the numbers of new 
HIV diagnoses to drive accrual into both arms of the study. Self-testing kits were distributed as 
a means of facilitating recruitment into the study by increasing the number of potential study 
participants visiting the study sites during the enrollment period. This study leveraged several 
methods for HIVST kit distribution:
 y Supervised distribution: HIVST kit-trained distributors provided pre-test instructions, including 
education on proper HIVST kit use and the importance for confirmatory testing, irrespective of 
result. The participant is informed that the HIVST is considered a screening test, and not meant 
to be used as a replacement for HIV testing at the health clinic. Peer educators are present 
to demonstrate the correct use and analysis of the test kits. In addition, participants are 
offered optional pre-test counseling, separate from the pre-test instruction information. Upon 
completion of testing, participants have the option to disclose the result to the distributor and 
receive post-test counseling if desired. 
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 y Unsupervised distribution: The unsupervised distribution relies on the written instructions 
and referral included in the self-test kit, without any additional supportive guidance, pre-test 
instructions, or demonstration of the self-test. 
 y Venue-based distribution: Venue-based HIVST kit distribution is implemented by partner 
organizations. Venue-based approaches for distribution target high-risk, and hard to reach 
populations. Target venues include sex work venues, bars, and nightclubs. Using the supervised 
distribution approach, peer educators provide individual instruction and training of HIVST kits. 
The participants receive the same guidance as highlighted under the supervised distribution 
approach.
 y Network-based distribution: The individual receives a test kit from the peer educator then 
distributes the HIVST to two other individuals using unsupervised distribution, which provides 
no verbal instruction or demonstration. The participant is encouraged to distribute the 
additional test kits to sexual partners or friends. In this study, the individual receiving the HIVST 
kits participates in supervised distribution and is provided with verbal description of use of the 
test and a demonstration.
Figure 2  Distribution approaches
Venue-based HIVST kit distribution was implemented by partner organizations and led by Enda 
Santé, who has extensive experience working in these communities, including providing services 
in venues and working with venue managers when applicable. This approach utilizes supervision 
Venue-based distribution Network-based distribution
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distribution of HIVST kits to distribute to high-risk and hard to reach populations, including men 
who have sex with men, female sex workers, trans women, and people who inject drugs. Target 
venues include sex work venues, bars, and nightclubs. Trained peer educators with experience 
in venue-based service provision led the distribution of HIVST. In venue locations, trained peer 
educations worked with venue managers, when applicable, and other peers to determine a 
location for HIVST kit distribution. Additionally, peer educators worked with each venue or 
site to specifically determine whether to approach individuals for recruitment, or to make the 
HIVST distributors available in the venue for potential participants to approach study staff for 
participation.
Distribution was conducted by trained Enda Santé peer educators, who provided brief instructions 
to each individual receiving a kit. The pre-test instructions include education on proper HIVST 
kit use, as well as the importance for confirmatory testing, irrespective of result. The individuals 
were informed that the HIVST is considering a screening test, and not meant to be used as a 
replacement for HIV testing at the health facility.
HIVST kits were also distributed using a network-based approach. The social network-based 
approach is focused on providing a primary recipient with one HIVST kit for themselves, and 
two additional test kits to distribute to individuals within their network. Social network-based 
distribution leveraged venue-based distribution to engage the primary HIVST recipient, who 
received the HIVST kits directly from the trained distributor. The primary recipient then distributed 
to secondary receipts through indirect, unassisted/unsupervised distribution; secondary 
recipients only received written instructions and information contained within the HIVST kit. The 
individual receiving the HIVST kits was encouraged to distribute the additional test kits to sexual 
partners or friends.
Participation in the pre- and post-test survey was optional, and individuals were provided the 
HIVST kit regardless of participation. No information was collected from individuals not willing to 
participate in the study questionnaires.
Consent process
Individuals receiving the HIVST were asked if they wished to participate in a pre-and post-test 
survey. Individuals were informed that participation was voluntary, and they would receive the 
HIVST kit regardless of their participation in the survey. Using a consent script approved by 
the Johns Hopkins School of Public Health Institutional Review Board and the Comité National 
d’Ethique pour la Recherche en Santé in Senegal, the study staff explained the study, outlining 
the purpose, sequence of events, rights, and potential risks and benefits before beginning any 
research activities with the participant. The consent form was translated to French and Wolof by 
translators not affiliated with the study and back-translated to ensure accuracy. A paper copy of 
the consent form in French was available should any participant want to keep one for personal 
records. 
Individuals who did not complete their HIVST on site were asked to provide a phone number and/
or email address for the study staff to use for the follow-up survey. Participants were informed of 
the process and that call history and numbers are deleted after a call has been made. 
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Children and adults lacking capacity to consent were considered ineligible to participate in the 
study, therefore we did not obtain a legally authorized representative’s signature.
Study implementation and data collection
HIVST kits were distributed through venue-based approaches and network based-approaches as 
described in the recruitment process. The instructions included in the kit were provided in French 
and Wolof, and adapted to the Senegalese context. For those who tested positive with the HIVST 
kits, the referral provided inside the kit directed the individual to a study site in order to facilitate 
the linkage to ART.
Individuals receiving the HIVST were asked during the distribution if they wished to participate 
in an optional pre-and post-test survey. The pre-test survey was conducted at the venue of 
distribution, in a private room, and by a trained interviewer. The post-test survey was conducted 
over the phone two weeks after the kit was distributed.
The survey collected information about demographic characteristics, socioeconomic status, 
behavioral characteristics, health and HIV treatment history, and HIV acquisition risks. This 
also collected information on HIV testing history, specifically recent use of HIVST. The post-test 
survey asked implementation outcomes including the use of HIVST, HIVST results, acceptability, 
routinization, feasibility, and adoption.
Self-testing was not documented for all individuals who presented at the government health 
clinics. However, clinicians assessed the reasons for confirmatory testing, though this was not 
documented unless the people chose to enroll into the RCT study. If enrolled into the study, the 
baseline assessment administered included question on HIVST knowledge and use.
HIVST kit distribution took place during the first six months of enrollment into the study. No 
personal Identifier was collected during the distribution of HIVST kits. A unique idenitifier code 
(UIC) was generated for each participant and was constructed using information known only to 
them. The code was formulated in consultation with members of the target populations through 
a recently implemented study in Senegal (IRB00005832) to contain questions that are easily 
answered, reproducible, culturally appropriate, individually unique, and that members of the 
target populations will be comfortable answering. During the process of creating the unique ID 
code with the participant, the study team member indicated that they only needed to respond 
with the appropriate number(s) or letter(s) to the question and do not need to give the full 
response (e.g., participant only need to provide the first letter of the city, rather than state the full 
name of the city). Doing so enables an additional sense of privacy for the participants.
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The UIC was constructed as follows:
L1 L2 L3 L4 N1 N2 N3 N4 L5 L6
L=Letter N=Number
Example: AAAA0101AAA
1. What are the first two letters of the city/town in which you were born? (L1L2)
2. What are the first two letters of the month in which you were born? (L3L4)
3. How many living brothers from the same mother do you have? (use 0# or 00 for less than ten 
or zero brothers from the same mother, respectively) (N1N2)
4. How many living sisters from the same mother do you have? (use 0# or 00 for less than ten or 
zero sisters from the same mother, respectively) (N3N4)
5. What are the first two letters of the neighborhood in which you currently live? (L5L6)
Data analysis
Implementation outcomes were used to assess the use of self-testing including uptake, 
routinization, acceptability, and long-term feasibility. Multiple broadly accepted indicators were 
used for each of these determinants of implementation. Specifically, implementation results were 
assessed to inform the use of rapid-kit-based self-testing as a strategy of finding new PLHIV that 
are not testing via traditional approaches.
Demographic characteristics, HIV testing history, and HIV risk behaviors were analyzed from 
pre-test questionnaires. Use and acceptability of HIVST was determined from post-test results. 
Pre- and post-test results were analyzed separately to understand crude estimate and prevalence 
among the pre- and post-test study populations. The pre- and post-test data were linked through 
the UIC of the participant. 
To assess self-testing for potential increase in HIV diagnosis in the health facilities, we conducted 
a pre/post assessment to compare numbers of individuals presenting with new diagnoses to 
specific referral clinics before and after the implementation of self-testing. Measurement of 
individuals presenting with new diagnoses prior to self-testing distribution was obtained through 
historical facility health records. Pre/post assessment also included implementation outcomes to 
assess confirmatory testing and linkage to care.
Logistic regression was used to assess the crude relationship between HIV testing history 
(first-time vs. previous testers), demographic characteristics, and HIV risk behaviors. Multiple 
multivariable logistic regression models were developed to separately assess each demographic 
characteristic, HIV testing history, and HIV risk behaviors as primary predictors of first-time testers 
and adjusted for a priori demographic characteristics. Pearson’s Chi squared tests were used to 
assess the crude relationships between first-time testers and HIVST use and acceptability, as well 
as the relationships between self-reported HIVST result and use and demographic characteristics. 
A significance value of p < 0.05 was used for all analyses.
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Results
Baseline characteristics: Pre-test survey results
From the 1,144 participants that completed the pre-
test survey, 47 percent had never previously received 
an HIV test and were thus classified as first-time 
testers. Twenty-seven percent had had some history 
of HIV testing but had not been tested within the last 
12 months, and only 26 percent had tested within 
the last 12 months (Figure 3).
Furthermore, we analyzed HIV testing histories 
among self-reported key populations (n=370) 
including FSW, male sex workers (MSW), MSM, PWID, 
and trans women (Table 1). Approximately half of 
participants who identified as MSM, MSW, PWID, or trans women reported never having been 
administered an HIV test. Among female sex workers, the proportion of first-time testers was 
lower at approximately 21 percent, and the proportion that had tested within the last 12 months 
was 52 percent. This was expected given the legalization of sex work sex work and institution of a 
registration system dependent on annual HIV testing.
First-time
tester
Tested, but not 
in the last 
12 months
Tested in 




Figure 3  HIV testing history among study 
                participants
Table 1  HIV testing history among key populations
Self-reported key 
populationx
Total HIV testing history
First time tester Yes, but not in the 
last 12 months
Yes, within the 
last 12 months
n/N % n/N % n/N % n/N % p-value
Key population (any) <0.001
Yes 370/1149 32 136/370 37 103/325 28 131/325 35
No 779/1149 68 400/774 52 205/774 27 169/774 22
Sex worker (all genders) <0.001
Yes 204/1085 19 54/204 27 53/204 26 97/204 48
No 881/1085 81 450/878 51 240/878 27 188/878 21
Female sex worker <0.001
Yes 155/1085 14 32/155 21 43/155 28 80/155 52
No 930/1085 86 472/927 51 250/927 27 205/927 22
Male sex worker 0.239
Yes 48/1085 4 22/48 46 9/48 19 17/48 35
No 1037/1085 96 482/1034 47 284/1034 28 268/1034 26
Men who have sex with 
men
0.923
Yes 174/1149 15 80/174 46 49/174 28 45/174 26
No 975/1149 85 456/970 47 259/970 27 255/970 26
People who inject drugs 0.184
Yes 42/1131 4 25/42 60 7/42 17 10/42 24
No 1089/1131 96 500/1084 46 297/1084 27 287/1084 27
Transgender women 0.242
Yes 20/1148 2 11/20 55 7/20 35 2/20 10
No 1128/1148 98 525/1123 47 300/1123 27 298/1123 27
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The study also analyzed the relationship between demographic characteristics such as age 
and sex at birth and being a first-time tester (Table 2). We observed that a large proportion, 56 
percent, of those identifying as men were first-time HIV testers. Women, meanwhile, were first-
time testers in 39 percent of the cases. After adjustment, men were found to have 2.71 (2.08, 
3.52) increased odds of being a first-time tester as compared to females.
When analyzing participant testing rates by age, almost 63 percent of young adults (aged 18–
24) were found to never having been administered an HIV test. Those aged 25–30 years were 
meanwhile found to be first-time testers 46 percent of the time, and those aged 31 and over were 
first-time testers 38 percent of the time. After an adjustment for region and sex, young adults had 
2.84 (2.07, 3.90) increased odds of being a first-time tester when compared to participants 31 
years and older. 
Table 2  First-time testers: Young adults and males
Characteristics HIV testing history




OR aOR* 95% CI p-value
n/N % n/N % n/N %
Age <0.001
 18–24 286/1130 25 179/285 63 106/285 37 2.75 2.84 2.07,3.90 <0.001
 25–30 370/1130 33 169/367 46 198/367 54 1.39 1.32 1.00,1.76 0.063
 31+ 474/1130 42 171/444 38 293/473 62 Ref Ref
Sex at birth <0.001
 Female 607/1148 53 233/604 39 371/604 61 Ref Ref
 Male 541/1148 47 303/539 56 236/539 44 2.04 2.71 2.08,3.52 <0.001
*Adjusted for region and sex
Follow-up results: Post-test survey results
Among the 817 individuals who participated in the post-test survey two weeks post-distribution, 
94 percent reported having used the HIVST kit. Fifty-four percent of participants chose to use the 
test at the distribution site while 46 percent used it at home. Eighty-nine percent of participants 
reported that they had used the self-test kit within two days of the distribution date, but only 10 
percent of individuals reported having sought confirmatory testing. A vast majority of participants, 
95 percent, reported that they would recommend the HIVST kit to others. Overall, we found that 
use and acceptability of HIVST did not significantly differ between first-time testers and those with 
a previous testing history.
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Figure 4  Use and acceptability of HIVST
The study then analyzed the reactivity of HIVST 
test results (Figure 5). Among post-test survey 
participants that self-reported their at-home test 
results, 3 percent reported a reactive, or positive, 
result. Meanwhile, 2 percent reported having 
received an invalid result. Among tests that were self-
administered at the distribution sites rather than at 
home, 5 percent of results were reactive.
Among participants that self-reported a reactive result, 63 percent were first-time testers and 37 
percent had a previous testing history. Those that obtained invalid results were first-time testers 
75 percent of the time and had a testing history 25 percent of the time. Meanwhile, from among 
those with negative test results, 57 percent had a testing history while 43 percent did not. Overall, 
the HIVST results were found to be statistically significantly associated with participants’ previous 
testing history.
We further analyzed HIVST reactivity results by place 
of test use, participant sex at birth, and presence 
or lack of confirmatory testing. Among participants 
with invalid, or undetermined results, 92 percent 
self-administered the tests at home. This indicates 
that there may be some incorrect use or reading of 
the HIVST among those that administered at home. If 
these were to be used at home more widely, we would 
consider providing additional information or guidance 
for those self-administering. 
We described earlier that 10 percent of all participants 
surveyed using the post-test sought confirmatory testing 
after their self-administered HIVST. Among participants with reactive results, 42 percent did not 
seek confirmation of their results. Meanwhile, among participants with an invalid result, none 
confirmed their results.
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Figure 7  Reactivity of HIVST
Discussion
The results show that HIVST can effectively engage those that have never previously received HIV 
testing, first-time testers, in Senegal. This includes key populations like sex workers, men who 
have sex with men, injectable drug users, and trans women, as well as men and young adults who 
are often not reached by traditional testing programs. 
Approximately half of MSW, MSM, PWID, and transgender women reached through HIVST 
reported not having previously tested for HIV. Few programs currently exist to provide tailored 
health services to PWID and transgender women in Senegal, and this study suggests that HIVST 
may provide an opportunity for PWID and transgender women to increase uptake of testing in this 
context. 
The emergence of social media and technology to engage young adults through social and 
sexual networks may provide an avenue for increasing uptake of HIV testing services for these 
populations (Perrin 2015). Mobile phone apps have also been shown to be acceptable among 
young MSM in other settings and have been used to assess risk and coordinate HIVST distribution 
(Sullivan & Driggers 2017; De Boni et al. 2017; Smith et al. 2017). HIVST web-based delivery 
has been acceptable across settings, including sub-Saharan Africa, and may provide further 
opportunity to increase uptake and frequency of testing among young MSM (Sullivan & Driggers 
2017; De Boni et al. 2017; Smith et al. 2017). Mobile technology may also be an opportunity to 
reach individuals in rural areas where program coverage and access to services is less, such as 
the region of Ziguinchor (Sullivan, Grey & Rosser 2013). 
Expanding access to HIVST may increase the coverage and frequency of HIV testing among key 
populations, and could thus have a role in linking PLHIV to diagnosis and treatment services, 
potentially helping to mitigate the HIV epidemic in Senegal. Connecting HIVST with confirmatory 
testing and linkage to care was a challenge during the implementation of this study. HIVST 
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strategies in Senegal may require more active mechanisms for follow-up and support in order to 
improve the pipeline from self-testing to confirmatory testing and care.
This small-scale implementation highlights the importance of leveraging existing structures and 
programs for distribution. However, adoption and integration of HIVST into existing programs will 
require a revision of the current HIV testing targets for programs in Senegal. HIVST indicators have 
been incorporated into the PEPFAR Monitoring, Evaluation, and Reporting (MER 2.0) Indicator 
Reference Guide representing appropriate indicators for collection in HIV testing programs 
(PEPFAR 2017). Notably, the HIV testing yield for programs may decrease if HIVST are included, 
though there will be a lower cost per test offered (Cambiano et al. 2015). Sustained engagement 
with the Senegalese government and other stakeholders will be needed in order to strategize the 
implementation and scale-up of HIV self-testing in Senegal.
AIMS 2 AND 3: CASE MANAGEMENT VS. STANDARD OF CARE
Overview
This study assessed the Senegalese SOC and CM in order to compare the effectiveness and 
durability in achieving SVS among PLHIV in Senegal. The SOC for treatment support for PLHIV 
in Senegal included facility-based ART initiation and follow-up systems leveraging appointment 
books without active reminders. All arms of the study, including SOC, included referrals for ART 
irrespective of CD4 counts for people who arrived at the test clinics—i.e., “test and treat.” 
Methods
The CM intervention was a multi-step process to coordinate care and provide a family-like 
support system for PLHIV. Peer health navigators received a capacity building training in case 
management at each study site as part of the intervention. The training's goal was to reinforce 
their health navigation capacities, train them in case management, and provide them with the 
tools to adequately fulfill their role as new case managers. 
After assignment of a case manager, the approach had five key components: 1) initial meeting 
between person living with HIV and case manager; 2) follow-up meeting between case manager 
and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls 
from case manager; and 5) face-to-face meetings between case manager and participant every 
six months. Each component is outlined below:
1. The initial meeting between person living with HIV and case manager to establish 
expectations and reflect upon treatment goals.
2. Following this initial meeting, the case manager and participant meet again within two weeks 
to finalize goals and to focus on skills and self-efficacy building to achieve treatment goals. 
During this visit, the person living with HIV determines if he/she wants to receive the standard 
level of text messages and calls or if he/she desires additional interaction.
3. Automated text messages are sent every two weeks to provide support and further promote 
self-efficacy (e.g., tips for remembering to take treatment, nutritional advice, condom 
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negotiation, and information about signs of co-infections). The content of the SMS was 
finalized based on consultations with multiple stakeholders to ensure that they are effective 
yet confidential. We consider the SMS as a core component of the interventions. 
4. Monthly phone calls from the case manager to review treatment goals, adherence 
performance and challenges, and logistics support; participants may also call the case 
manager anytime during the month or place a free “Please Call Me,” which is returned as 
soon as possible by the case manager.
5. Every three months following the initial sessions, the case manager will meet face-to-face 
with the participant and comprehensively evaluate achievement of goals and set new goals 
going forward. Clinic appointment reminders will also be sent to participants, both 7 days and 
24 hours prior to follow-up, and participants will be triggered with a phone call by the case 
manager if the appointment was unexpectedly missed.
Sample size
The total proposed sample size for the randomized controlled trial for case management across 
both cities was 596 participants.
To estimate the sample size for this study, we assumed a cumulative 20 percent loss to follow-up 
at the end of the study period. We assumed this loss to follow-up to be distributed equally across 
each 3-month study visit, resulting in a total sample size required for randomization of 596 PLHIV 
who are not virally suppressed. The sample size calculation was computed under the assumption 
that annual viral suppression rate is as high as 60 percent under SOC, and would increase to 
a minimum of 80 percent among those receiving the CM intervention. Thus, with a sample size 
of 596 with 298 in each of the two cities with study sites, we would have 90 percent power at 5 
percent level to detect a difference of at least 20 percent between the control and intervention. 
The two sites have been powered independently and pooling of data only takes place if there is 
sufficient homogeneity of results.
 Table 3  Sample calculation size table 
Alpha Power N N1 N2 Delta p1 p2
0.05 80% 238 119 119 18% 30% 48%
0.05 90% 238 119 119 21% 30% 51%
0.05 80% 238 119 119 19% 40% 59%
0.05 90% 238 119 119 22% 40% 62%
0.05 80% 238 119 119 19% 50% 69%
0.05 90% 238 119 119 21% 50% 71%
0.05 80% 238 119 119 18% 60% 78%
0.05 90% 238 119 119 20% 60% 80%
Notes: N=Total sample size by site/city, N1/N2= Standard of care/Intervention sample size, p1 = Annual viral suppression rate 
under standard of care, p2= Viral suppression rate under the proposed intervention
Effect size estimates for a two sample proportions test is shown in Figure 8. This figure illustrates 
the magnitude of effect needed to observe a significant difference (p<0.05) between the control 
and intervention groups. The control group proportion is representative of the 12-month viral 
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suppression rate among those living with HIV from SOC. The range of assumptions is from 30 to 
70 percent viral suppression (VS) at 12 months with a conservative estimate that 60 percent are 
VS at that time point. The Y-axis refers to the effect size of the intervention with ranges from 16 
to 24 percent effect and then X-axis referring to the power from 80 to 95 percent power. With a 
conservative estimate of 20 percent effectiveness in SVS as compared to SOC and a baseline VS 
of 12 months of 60 percent, we will have 90 percent power and type-1 (alpha) error of 5 percent 
with a sample size of 119 in each study arm in each study site. Thus, we require 238 per study 
site, and with an assumed annual loss to follow-up of 20 percent, we require 298 per city or a 
total of 596 participants across two clinics in Dakar and one clinic in Ziguinchor.
Figure 8  Effect size
The total sample size for the RCT study across both cities was 596.
Participants and recruitment
The study population for the CM vs. SOC intervention of this study is PLHIV who are not virally 
suppressed, and are included independent of their CD4 count. Eligible participants were 18 
years of age or older at the time of enrollment into the study. All study participants must also 
be residents of Senegal for at least three months and plan to reside in Dakar or Ziguinchor for 
at least the next year. We assessed acquisition and transmission risk factors among the PLHIV 
included in our study but individuals were not be included or excluded based on behavioral risk 
factors. Thus, while this study didn’t specifically limit inclusion to MSM or FSWs, there was an 
expectation that a significant proportion of people diagnosed with HIV in Senegal are members of 
these groups or other key populations, and ensuring sensitive services was crucial.
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Inclusion criteria
 y 18 years of age or older
 y Mentally sound and capable of providing consent to participate
 y Agrees to complete HIV and syphilis testing
 y Speaks either French, Wolof or both
 y Provided informed consent to participate in the study
 y Resident of Senegal for the past 3 months
 y Intention to live in Dakar or Ziguinchor for the next 12 months
 y Agrees to complete all required biological testing described in the consent form and receive 
results
Exclusion criteria
 y Under 18 years of age
 y Demonstrates mental incapacity, under the influence of substances, or any other illness 
preventing comprehension of the study procedures and informed consent
 y Does not agree to complete all required biological testing described in the consent form or 
receive results
 y Has not provided informed consent to participate in the study
Recruitment process
Recruitment and participant enrollment into the RCT took place at the health facility assigned 
as a study site. Self-testing kits were used as a means to increase the number of potential study 
participants visiting the designated health facilities and facilitate recruitment into the study. 
However, study participants were not excluded if not recruited through the self-testing kits. 
Participants who visited the study sites and tested positive for HIV were assessed for eligibility 
into the study. Trained health facility staff provided potential study participants with information 
about the study in broad terms. The initial information provided included the target population of 
the study, as well as the overall objective of the study. The potential participant was then referred 
to study staff within the study site, if they chose to be assessed for eligibility and enrollment.
The work of informing and ultimately consenting participants was done by the study staff, who 
were the same staff members that worked on this study throughout. Throughout the consent and 
discussions, the study team emphasized that participation was voluntary and would not impact 
their involvement with the health facility, and that engaging in the study would have no bearing on 
their level of service from health facility.
Once the participant was determined to be eligible, they were enrolled into the study by trained 
study staff.
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Consent process
Laboratory technicians, nurses, or quantitative interviewers obtained informed consent from 
participants. All study staff members with direct contact with study participants were certified in 
CITI ethics training or other comparable training programs, completed an in-person ethics training 
conducted by the study investigators, and were supervised by the local PI to ensure adherence to 
study protocol and consent requirements, ethical and confidential practices with participants, and 
data management.
All consent discussions occurred at the study site. The consent form was reviewed and an 
opportunity for participants to ask questions was provided. Informed consent was provided by 
participants who met the eligibility criteria prior to the beginning of any research activities with the 
participant. If eligible, the participant was informed about the cohort. At this point, participants 
were required to provide a phone number and/or email address for the study staff to use for 
appointment reminders. Participants were informed of the process, and that call history and 
numbers would be deleted after a call has been made. Using a consent script approved by JHSPH 
IRB and the local IRB, the study staff explained the study, outlining the purpose, sequence of 
events, rights, and potential risks and benefits to participants. Other aspects of the consent 
process were identical to the baseline assessment, but the consent script was different from the 
consent script of the baseline assessment. Participants were offered a copy of the consent form 
but were not required to take it.
We documented if a potential participant declined to participate during the consent process. The 
reason for not participating was recorded by the interviewer. Additionally, if a participant retracted 
their consent at any point throughout the study, the reason for this retraction was documented by 
the interviewer.
The interviewer asked the participant a series of eligibility questions to assess whether he or she 
met the criteria. We obtained signatures from participants rather than using oral consent per 
requirements from the Senegalese ethics committee.
Adults lacking capacity to consent were ineligible to participate in the study, therefore we did not 
obtain a legally authorized representative’s signature. To protect participants’ privacy, we did not 
include a witness to the consent process.
Study implementation and data collection
Peer health navigators received a capacity building training in case management at each study 
site as part of the intervention. The training's goal was to reinforce their health navigation 
capacities, train them in case management, and provide them with the tools to adequately fulfill 
their role as new case managers. 
Eligible participants recruited through the study site health facilities went through the consent 
process in private rooms within the project office and completed a structured 1-hour interviewer-
administered questionnaire, which served as the baseline assessment. Participants were enrolled 
into the study by trained study staff at a study site.
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Participants assigned to the CM intervention received Standard of Care treatment, and were 
provided CM support. After assignment of a case manager, the CM approach had five key 
components:
1. The initial meeting between person living with HIV and case manager to establish expectations 
and reflect upon treatment goals.
2. Following this initial meeting, the case manager and participant met again within two weeks 
to finalize goals and to focus on skills and self-efficacy building to achieve treatment goals. 
During this visit, the person living with HIV determined if he/she wanted to receive the 
standard level of text messages and calls or if he/she desired additional interaction.
3. Automated text messages were sent every two weeks to provide support and further 
promote self-efficacy (e.g., tips for remembering to take treatment, nutritional advice, 
condom negotiation, and information about signs of co-infections). The content of the SMS 
was developed based on consultations with multiple stakeholders to ensure that they were 
effective yet confidential. 
4. Monthly phone calls from the case manager reviewed treatment goals, adherence 
performance and challenges, and logistics support; participants could also call the case 
manager anytime during the month or place a free “Please Call Me,” which was returned as 
soon as possible by the case manager.
5. Every three months following the initial sessions, the case manager met face-to-face with the 
participant and comprehensively evaluated achievement of goals and set new goals going 
forward. Clinic appointment reminders were also sent to participants, both 7 days and 24 
hours prior to follow-up, and participants were triggered with a phone call by the case manager 
if the appointment was unexpectedly missed.
Case managers filled out a case manager form at each visit with each study participant. The 
aim of this data collection was to understand the implementation of the intervention from the 
perspective of the case managers. Case managers conducted visits with participants to provide 
supportive services, assess barriers to ART, and provide referrals. Therefore, the case managers 
provided information for the purpose of the study on the visit and their assessment with the 
participants. The information included barriers to participants’ adherence to ART and referrals 
provided to the participant. These forms were collected from the case managers for each 
participant visit.  
All study visits took place at the study site representing an existing health facility in either Dakar 
or Ziguinchor. Each study visit lasted approximately two hours.
Table 4  Study visits
Visit Month Biological testing Questionnaire Max duration
1 (Baseline) 0 Yes Full assessment 2 hours
2 3 No Abbreviated 1 hour
3 6 Yes Full assessment 2 hours
4 9 No Abbreviated 1 hour
5 12 Yes Full assessment 2 hours
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Baseline assessment of study participants included a questionnaire and biological testing. The 
baseline questionnaire assessed demographic characteristics, socioeconomic status, mobility 
and migration history, behavioral characteristics, health and HIV treatment history, and HIV 
acquisition risks. The baseline assessment also collected information on HIV testing history, 
specifically recent use of HIVST. For those who received an HIVST kit, there was significant 
attention on the measurement of implementation outcomes including the use of HIVST, HIVST 
results, acceptability, routinization, feasibility, and adoption.
Follow-up involved visits at 3, 6, 9, and 12 months after the first visit. Questionnaires were 
administered at each visit. Questionnaires assessing behavioral characteristics, mental health, 
social support, and ART treatment adherence were administered at 6 months and 12 months.
Abbreviated questionnaires were re-administered at three and nine months though no biological 
assessments were completed at these time points. The questionnaires leveraged existing 
instruments that have detailed assessments of implementation outcomes associated with 
HIVST; the use of iris for tracking and engagement in ART services; and enacted, perceived, and 
intersectional stigma. In addition, we used implementation indicators that explore measures of 
acceptability, fidelity, appropriateness, and routinization of the CM intervention.
Cost effectiveness of the CM approach
The data needed to later complete cost-effectiveness assessments of the use of CM intervention 
were collected as part of this study. From the participant perspective, we used a standardized 
questionnaire based on the WHO’s “Tool to Estimate Patients’ Costs” to assess the cost to 
individuals in accessing and maintaining participation in CM. Participant costs include: (a) lost 
wages and productivity required to attend the CM visits; (b) transportation and ancillary costs 
(e.g., food, childcare) necessary for attendance; (c) internet and cell phone use charges; and (d) 
costs associated with behavior change itself (e.g., cost of acquiring condoms and HIV tests, lost 
wages due to foregone risky sexual encounters). We also used two instruments: the brief version 
of the WHO Quality of Life instrument (WHOQOL-BREF5) and the EQ-5D6 to assess participants’ 
quality of life and health utility, respectively. The WHOQOL-BREF is a 26-item instrument that 
measures quality of life across four broad domains: physical health, psychological health, social 
relationships, and environment; the EQ-5D is a five-item survey that can provide estimates of 
health utility (score from 0 = death to 1 = perfect health). The use of these two instruments 
enabled us to capture not only the indirect effects of such interventions on reducing HIV 
transmission, but also their direct effects on individuals’ quality of life.
Cost-related data were collected from the healthcare perspective as well. These costs included 
(though were not limited to): (a) hiring and training of case managers; (b) monthly costs of 
preparing and delivering support through case managers; and (d) program implementation and 
oversight, including physical resources (e.g., office space), human resources, and overhead. 
Time requirements for each activity were measured by direct observation using time-motion 
studies; additional budgetary requirements were elicited through structured discussions with staff 
5https://www.who.int/tools/whoqol/whoqol-bref 
6https://euroqol.org/eq-5d-instruments/ 
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members and case managers. (However, no personal information was collected from staff or case 
managers).
Figure 9  Site flow
The study lasted 15 months from the time of the first participant enrollment to the last study 
visit. Each participant was part of the study for a maximum of 12 months. The cohort follow-up 
involved five study visits, lasting up to two hours each. Participants also had the opportunity for 
clinical visits and intervention activities, but these will vary by person and are separate from study 
visits.
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Measures were taken to ensure personal information of the study participants was protected 
during data collection and data storage. 
Data analysis
Effectiveness and durability of the CM approach
We estimated the effectiveness and durability of CM vs. SOC interventions focused on achieving 
SVS to inform the SOC. The primary effectiveness outcomes were SVS defined using quantitative 
viral load assessment with <400 copies/ml at 12 months after initial randomization. To 
compare the effectiveness and durability of CM programs vs. SOC to achieve SVS, we conducted 
a difference of proportions Intention to Treat (ITT) analysis comparing SVS at 12 months 
between participants randomized to CM vs. SOC. Interim analyses at 6 months of differences 
in viral suppression were also completed. Secondary outcomes include: 1) durability of viral 
load suppression among 6-month responders continuing CM vs. those randomized to SOC.; 2) 
loss-to-follow-up across arms; and 3) participant reported implementation outcomes including 
acceptability and routinization of the intervention. Loss to follow-up was compared across 
study intervention arms using GEE models with a binomial distribution and logit function and 
accounting for baseline characteristics using inverse probability treatment weights (this is 
necessary for this non-ITT analysis as people were re-randomized to new arms over time and thus 
benefits of randomization are lost). Uptake, acceptability, and intervention fidelity are described. 
Missing data were handled using multiple imputation if missing was at random and more than 5 
percent.
Cost-effectiveness of the CM approach
To determine the cost-effectiveness of the universal treatment approach using the CM 
intervention, we performed a comprehensive costing of our study intervention, from the 
perspectives of both the healthcare system and the participants. Our costing methodology 
followed World Health Organization (WHO) recommendations for cost-effectiveness analysis, with 
estimates of unit costs compared against WHO’s CHOosing Interventions that are Cost-Effective 
(CHOICE) global estimates for countries in Senegal’s region.
Results
Participants demographic characteristics
The sample included 573 participants that were allocated to receive either standard of care 
(n=281) or the case management treatment (n=292). The two groups were compared based on 
characteristics such as age, education, employment status, marital status, living situation, sex 
and gender, city, key population status, and treatment status. 
The demographic breakdown of the two study arms, detailed in Table 5, show that randomization 
was successful given the similarity in characteristics. On average, participants were 36 years 
of age and the largest proportion (35%) had never attended school. Forty-two percent of the 
participants were unemployed while 24 percent were independent workers and 6 percent were 
students. Most participants were either married (44%) or single/never married (34%) while 14 
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percent were widowed. Most participants, 63 percent, indicated that they lived with family. Fifty-
six percent of participants indicated that their sex at birth was female, and 57 percent identified 
as female at the time of the intervention.
Among the SOC group, 21 percent of participants were sex workers while 24 percent were MSM. 
The proportion of these key populations was slightly smaller among the CM group, where 16 
percent of participants were sex workers and 21 percent were MSM. Forty-three percent of SOC 
participants were on treatment at the outset of the intervention while a majority, 89 percent, had 
been newly diagnosed with HIV. In the CM group 46 percent were on treatment and 85 percent 
were newly diagnosed. 
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n (%) n (%) n (%)
Age in years, mean (Interquartile range) 36 (28-46) 36 (27-47) 36 (28-46) 0.7837
Education
Never went to school 93 (33) 106 (36) 199 (35)  
Incomplete primary school 48 (17) 45 (15) 93 (16)  
Primary school complete 41 (15) 31 (11) 72 (13)  
Incomplete secondary school 51 (18) 49 (17) 100 (18)  
Complete secondary school 13 (5) 17 (6) 30 (5)  
Professional training 10 (4) 9 (3) 19 (3)  
University studies 14 (5) 19 (7) 33 (6)  
Other 11 (4) 15 (5) 26 (5)  
Refusal 0 (0) 1 (0.3) 1 (0.2) 0.744
Employment status
Unemployed 113 (40) 129 (44) 242 (42)
Retired 3 (1) 2 (1) 5 (1)
Training/student 17 (6) 14 (5) 31 (5)
Temporary work 2 (1) 0 (0) 2 (0.3)
Independent worker 70 (25) 66 (23) 136 (24)
Salaried (short-term contract) 12 (4) 10 (3) 22 (4)
Salaried (long-term contract) 8 (3) 11 (4) 19 (3)
Other 56 (20) 60 (21) 116 (20) 0.751
Marital status
Married 115 (41) 136 (47) 251 (44)
Single/never married 96 (34) 97 (33) 193 (34)
Divorced/separated 28 (10) 17 (6) 45 (8)
Widowed 41 (15) 41 (14) 82 (14)
In a relationship 1 (0.4) 1 (0.3) 2 (0.3) 0.374
Living situation
With family 179 (64) 180 (62) 359 (63)
With friends 9 (3) 2 (1) 11 (2)
Renting a place 69 (25) 72 (25) 141 (25)
Own a place 10 (4) 22 (8) 32 (6)
Dormitory 1 (0.4) 0 (0) 1 (0.2)
Other 13 (5) 16 (6) 29 (5) 0.072
Literacy
No 134 (48) 143 (49) 277 (48)
French 80 (29) 74 (25) 154 (27)
Wolof 13 (5) 11 (4) 24 (4)
French and Wolof 53 (19) 64 (22) 117 (20)
Don’t know 1 (0.4) 0 (0) 1 (0.2) 0.642
Sex at birth
Male 130 (46) 125 (43) 255 (45)
Female 151 (54) 167 (57) 318 (56) 0.405
Gender identify
Male 108 (38) 97 (33) 205 (36)
Female 155 (55) 174 (60) 329 (57)
Other 16 (6) 20 (7) 36 (6)
Refusal 1 (0.4) 0 (0) 1 (0.2)
Don't know 1 (0.4) 1 (0.3) 2 (0.3) 0.571
Region 
Dakar 146 (67) 154 (65) 300 (66)
Ziguinchor 73 (33) 84 (35) 157 (34) 0.659
Key populations
Sex workers* 59 (21) 46 (16) 105 (18) 0.154
Men who have sex with men** 66 (24) 61 (21) 127 (22) 0.562
Treatment
Newly diagnosed with HIV 249 (89) 249 (85) 498 (87) 0.236
On treatment 121 (43) 134 (46) 255 (45) 0.496
*Have you ever exchanged sex for money or goods? 
**Have you ever had sex (anal or oral) with a male?
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Cohort follow-up
Several avenues were targeted for the recruitment of study participants. The first lead was people 
newly screened through the HIV self-testing strategy that was deployed in all the study cities. The 
second lead was newly screened patients through the routine screening program at the study 
sites. The third option was to recruit newly screened and managed patients at the care sites who 
are referred to the study sites.
The first study visit was conducted at 
baseline (Visit 1), and was followed 
by four more visits at 3, 6, 9, and 12 
months. Figure 10 shows the number 
of participants in the SOC and CM 
intervention arms participating in each 
study visit. At the first study visit, 289 CM 
and 278 SOC group members participated 
in the three different sites. Both numbers 
decreased significantly during the 
second visit, with 186 CM and 199 SOC 
participants. A smaller decrease was 
seen during the third study visit, with 141 
participants from each of the two study 
arms, which was then followed by slight 
increases during the fourth and fifth visits. 
During the fifth and final visit, 168 CM and 
174 SOC participants took part in the study. 
There are several reasons for the lower number of participants in post-inclusion visits. First, there 
is the mobility of patients, especially key populations. Although the study criteria for participation 
required the individual to confirm that they would be staying in the study for at least the duration 
of the study, some patients moved to other parts of the country or sometimes even outside 
the country depending on their activities. In addition, the study period coincided with several 
moments of strike and protests by the health workers unions during which all activities were at a 
standstill at the various sites. Finally, there was the rain season during which a good part of the 
people in Casamance leave the cities to return to the remote villages and do not return until the 
end of the season. This is not specific to the study, but also impacts all follow-up of PLHIV in this 
region.
Disclosure and stigma
Participants shared experiences of disclosure and stigma attributable to HIV status and sexual 
behavior. Stigma from family and friends was measured as feeling excluded from family activities, 
feeling rejected by friends, and being spoken to in a negative manner. Stigma from healthcare 
workers was measured as feared or avoided seeking healthcare; felt mistreated, denied, or 
kept from health services; or felt spoken to negatively by a healthcare worker. Stigma from the 
community was measured as being afraid to be in public or having been verbally or physically 
















Figure 10  Participation in study visits by study arm
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were asked to participants who ever had sex in exchange for money or goods and/or had sex with 
men. 
HIV-related stigma 
Among the participants in the CM arm, 51 percent reported having shared their positive HIV 
status with a family member, and 28 percent in the SOC arm. Overall, a small proportion of 
participants reported having felt excluded by friends (3%) or from family activities (4%). In 
healthcare settings, only 9 percent participants shared having ever avoided seeking healthcare. 
No participant reported feeling mistreated or having been denied services by healthcare workers. 
Among the CM participants, 9 percent reported fear of being in public places and 2 percent of 
having been blackmailed, compared to 6 percent that were blackmailed in the SOC arm. No 
participant reported having ever been physically harassed or forced to have sex because of their 
positive HIV status in either study arm.








n (%) n (%) n (%)
Told family member HIV status 9 (28) 22 (51) 31 (41) 0.045
Stigma from family and friends
Felt excluded from family activities 2 (6) 1 (2) 3 (4) 0.391
Family member made a negative remark or gossiped 4 (13) 1 (2) 5 (7) 0.081
Felt rejected by friends 2 (6) 0 (0) 2 (3) 0.177
Healthcare
Feared seeking healthcare 2 (6) 4 (9) 6 (8) 0.630
Avoided seeking healthcare 2 (6) 5 (12) 7 (9) 0.382
Felt mistreated in a healthcare center 0 (0) 0 (0) 0 (0)
Denied or kept from health services 0 (0) 0 (0) 0 (0)
Felt healthcare worker made negative remarks or 
gossiped 
0 (0) 0 (0) 0 (0) .
Community
Afraid to be in public places 0 (0) 4 (9) 4 (5) 0.076
Verbally harassed 1 (3) 1 (2) 2 (3) 0.832
Blackmailed 2 (6) 1 (2) 3 (4) 0.391
Physically harassed 0 (0) 0 (0) 0 (0)
Sexual behavior-related stigma
MSM are often stigmatized by their social environment, family, or friends. This often leads to their 
exclusion or rejection because of their behavior or sexual orientation. In this study, the results 
show that out of 112 MSM surveyed at baseline, only nine felt comfortable enough to talk about 
their sexual orientation with their family or friends. Sixteen percent (n=18) have at least once 
been the victim of negative remarks from a family member about their sexual orientation. These 
remarks often lead to the exclusion of the from family activities (9%, n=10). These negative 
comments and/or exclusion from family activities were more prevalent among those in the 
standard care arm (19% and 16%) than those in the case management arm (2% and 13%).
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A few MSM participants, 14 percent (n=16), were often afraid to attend health facilities for their 
care needs, due to their perceived risk of stigmatization. This was more common among patients 
followed in standard care (19%) than those followed in case management (9%). However, the 
results of the study showed that it is rare for patients to be mistreated in a health facility because 
they are MSM—1 percent (n=1) reported this; or to be stigmatized by health providers, with 3 
percent (n=3) reporting this.
MSM reported experiencing stigma from the police. Eight MSM, or 7 percent, reported having 
been arrested by the police; five or 4 percent, had been harassed by the police; and three or 3 
percent, had been refused protection by the police because of their sexual orientation. 
Social stigma is common among MSM. Indeed, nine MSM, or 8 percent, said they were afraid to 
go to public places at least once because of their sexual orientation. They were often victims of 
verbal harassment (13%), physical harassment (12%), or blackmail (13%). 








n (%) n (%) n (%)
Told a family member sexual behavior 6 (10) 3 (6) 9 (8) 0.337
Family and friends
Felt excluded from family activities 9 (16) 1 (2) 10 (9) 0.015
Family member made a negative remark or gossiped 11 (19) 7 (13) 18 (16) 0.244
Felt rejected by friends 8 (14) 1 (2) 9 (8) 0.063
Healthcare
Feared seeking healthcare 11 (19) 5 (9) 16 (14) 0.132
Avoided seeking healthcare 8 (14) 4 (7) 12 (11) 0.261
Felt mistreated in a healthcare center 1 (2) 0 (0) 1 (1) 0.328
Denied or kept from health services 0 (0) 0 (0) 0 (0)
Felt healthcare worker made negative remarks or 
gossiped 
2 (3) 1 (2) 3 (3) 0.590
Uniformed officer
Felt not protected by uniformed officer 3 (5) 0 (0) 3 (3) 0.087
Avoided carrying condoms 6 (10) 3 (6) 9 (8) 0.337
Condoms confiscated or destroyed 0 (0) 1 (2) 1 (1) 0.302
Felt harassed or intimated 4 (7) 1 (2) 5 (4) 0.189
Arrested on charges related to homosexuality 6 (10) 2 (4) 8 (7.) 0.165
Community
Afraid to be in public places 3 (5) 6 (11) 9 (8) 0.260
Verbally harassed 10 (17) 5 (9) 15 (13) 0.202
Blackmailed 12 (21) 3 (6) 15 (13) 0.017
Physically harassed 10 (17) 3 (6) 13 (12) 0.050
Forced to have sex 19 (33) 8 (15) 27 (24) 0.023
Like MSM, many of the SW surveyed were also stigmatized because of their sexual behaviors and 
practices. This stigmatization generally comes from their social environment, family, or friends. In 
38  ■  Leveraging adaptive implementation strategies to achieve universal coverage of ART in Senegal
this study, the results show that out of 33 interviewed SW, only five (15%) felt comfortable enough 
to talk to a family member about their situation, four SW (12%) were victims of negative remarks 
by a family member because of their activities or behavior, and three (9%) said they were rejected 
by their friends for reasons related to their sex work. 
As among MSM, the percentage of SW who reported perceiving stigma in the medical setting was 
low. No SW participant reported being afraid to go to health facilities because of their profession. 
A minority of SW reported having been stigmatized by the police. Two (6%) said they lacked police 
protection. Three (9%) were victims of police harassment, and 6 (18%) were victims of arrest by 
the police in the course of their work. 
Social stigma is the phenomenon most felt among SW in this study. In addition to stigmatization, 
FSWs also reported being survivors of violence. This violence can take the form of physical 
assault (15%), fear of going to public places (9%), verbal harassment (12%), blackmail (18%), or 
assault or sexual violence (24%).
Table 8  Disclosure and sex work-related stigma among sex workers at baseline
SOC 
(n=22)
CM (n=11) Total 
(n=33)
p-value
n (%) n (%) n (%)
Told a family member sexual behavior 4 (18) 1 (9) 5 (15) 0.492
Family and friends
Felt excluded from family activities 3 (14) 0 (0) 3 (9) 0.199
Family member made a negative remark or gossiped 4 (18) 0 (0) 4 (12) 0.131
Felt rejected by friends 3 (14) 0 (0) 3 (9) 0.199
Healthcare
Feared seeking healthcare 0 (0) 0 (0) 0 (0)
Avoided seeking healthcare 0 (0) 0 (0) 0 (0)
Felt mistreated in a healthcare center 0 (0) 0 (0) 0 (0)
Denied or kept from health services 0 (0) 0 (0) 0 (0)
Felt healthcare worker made negative remarks or 
gossiped 
0 (0) 0 (0) 0 (0)
Uniformed officers
Felt not protected by uniformed officer 2 (9) 0 (0) 2 (6) 0.302
Avoided carrying condoms 3 (14) 0 (0) 3 (9) 0.199
Condoms confiscated or destroyed 2 (9) 0 (0) 2 (6) 0.302
Felt harassed or intimidated 2 (9) 1 (9) 3 (9) 1.000
Arrested on charges related to prostitution 3 (14) 3 (27) 6 (18) 0.338
Community
Afraid to be in public places 2 (9) 1 (9) 3 () 1.000
Verbally harassed 4 (18) 0 (0) 4 (12) 0.131
Blackmailed 5 (23) 1 (9) 6 (18) 0.338
Physically harassed 4 (18) 1 (9) 5 (15) 0.492
Forced to have sex 5 (23) 3 (27) 8 (24) 0.774
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Condom use
During the first, third, and fifth visits, participants received full assessments through 
questionnaires, including questions aiming to measure behavioral characteristics such as 
condom use. Table 9 shows the condom usage results from these three visits for both the SOC 
and CM treatment arms. 
Participants were asked to indicate how often they used a condom for sex with their principal 
partners over the past 30 days. The percentage of SOC participants indicating they had never 
used one decreased from 33 percent to 16 percent between the baseline and fifth visit. In the 
CM group, meanwhile, 28 percent initially indicated they had never used a condom with their 
principal partners over the past 30 days. This number decreased to 10 percent on the third visit 
and increased to 13 percent during the fifth visit. The proportion of participants that indicated 
they had used a condom with their principal partners rarely, from time to time, or often remained 
below 5 percent for all treatment arms and visits. The proportion of SOC participants indicating 
that they had always used a condom with their principal partners over the last 30 days increased 
from 10 percent to 20 percent between the first and last visit. The CM group, meanwhile, reported 
an increase from 11 percent to 21 percent between the first and third visits, and then decreased 
to 19 percent in the final visit.
Participants were also asked how often over the past 30 days they had used a condom for sex 
with their casual partners. Among the SOC arm, 24 percent of participants initially reported 
never having used a condom. This proportion decreased to 8 percent during the third visit and 
to 7 percent during the fifth visit. The CM arm saw an initial decrease from 25 percent during 
the first visit to 4 percent during the third visit. However, the number increased to 9 percent 
during the fifth visit. Similarly, the proportion of CM participants indicating they had always used 
a condom increased from 8 percent during the baseline visit to 18 percent during the third visit, 
and ultimately decreased to 16 percent during the fifth visit. Among SOC participants, 11 percent 
initially indicated always using a condom with their casual partners. This figure increased to 19 
percent during the third visit and decreased to 15 percent during the fifth visit. In the case of 
condom usage for sex with casual partners, less than 3 percent of participants indicated using a 
condom rarely, from time to time, or often for all treatment arms and visits
Mental health
Mental health was assessed using the Patient Health Questionnaire (PHQ-9). A score of 0–4 
suggests minimal or no depression, 5–9 mild depression, 10–14 moderate depression, 15–19 
moderately severe depression, and 20–27 severe depression. 
Table 10 illustrates the presence and severity of depression at the first, third, and fifth visit. 
Overall, the severity of depression decreased at all levels in both the SOC and CM arm. 
Between the first and fifth visit, the percentage of participants in the SOC arm with no depression 
increased from 64 percent to 87 percent. This trend persisted as the proportion of participants 
experiencing mild depression decreased from 24 percent to 11 percent. Similarly, those 
experiencing moderate levels of depression decreased from 9 percent to 0.6 percent during the 
third visit, but increased to 2 percent during the fifth visit. 
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Participants in the CM arm also displayed a decrease in the burden of depression between 
the first, third, and fifth visit. At the first visit, 65 percent of participants indicated an absence 
of depression, 89 percent during the third visit, and 84 percent during the fifth visit. While still 
displaying an overall decrease, there was a slight increase exhibited between the third and fifth 
visit. At the first visit, 25 percent of participants in the CM arm experienced mild depression, 
10 percent during the third visit, with a slight increase to 13 percent during the fifth visit. One 
percent of participants experienced moderately severe depression at the first visit, and no 
signs at the third and fifth visit. This figure demonstrates a slight increase in the proportion of 
depression between the third and fifth visits, with an overall decrease in its severity among both 
the SOC and CM arms. 
Table 10  Mental health outcomes—12 months follow-up














n (%) n (%) n (%) n (%) n (%) n (%)
None 179 (64) 189 (65) 135 (83) 147 (89) 152 (87) 141 (84)
Mild 66 (24) 73 (25) 23 (14) 17 (10) 19 (11) 22 (13)
Moderate 26 (9) 24 (8) 3 (2) 1 (0.6) 3 (2) 5 (3)
Table 9  Condom use among participants in study arms—12-month follow up














n (%) n (%) n (%) n (%) n (%) n (%)
Condom use with 
principal partners
Never 93 (33) 83 (28) 22 (14) 16 (10) 28 (16) 21 (13)
Rarely 9 (3) 6 (2) 4 (3) 4 (2) 5 (3) 5 (3)
From time to time 9 (3) 13 (5) 5 (3) 2 (1) 5 (3) 7 (4)
Often 10 (4) 11 (4) 1 (0.6) 4 (2) 2 (1) 3 (2)
Always 27 (10) 31 (11) 36 (22. 35 (21) 35 (20) 31 (19)
Has not had sex 132 (47) 148 (51) 94 (58) 102 (62) 98 (56) 101 (60)
Refusal 1 (0.4) 0 (0) 0.687 0 (0) 2 (1) 0.392 1 (0.6) 0 (0) 0.843
Condom use with 
casual partners
Never 68 (24) 72 (25) 13 (8) 7 (4) 12 (7) 15 (9)
Rarely 5 (2) 5 (2) 3 (2) 1 (0.6) 0 (0) 3 (2)
From time to time 6 (2) 4 (1) 2 (1) 1 (0.6) 1 (0.6) 0 (0)
Often 7 (3) 8 (3) 1 (0.6) 1 (0.6) 5 (3) 3 (2)
Always 30 (11) 24 (8) 31 (19) 29 (18) 26 (15) 26 (16)
Has not had sex 154 (55) 169 (58) 110 (68) 125 (76) 130 (75) 118 (70)
Refusal 8 (3) 3 (1) 2 (1) 0 (0) 0 (0) 1 (0.6)
Don’t know 3 (1) 7 (2) 0.586 1 (0.6) 1 (0.6) 0.523 0 (0) 2 (1) 0.306
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Moderately 
severe
6 (2) 4 (1) 1 (0.6) 0 (0) 0 (0) 0 (0)
Severe 2 (0.7) 1 (0.3) 0.880 0 (0) 0 (0) 0.336 0 (0) 0 (0) 0.598
Substance abuse
More than 90 percent of respondents at baseline, third, and fifth visits said they had never 
consumed alcohol in the last three months prior to the survey. Among SOC respondents, 5 
percent reported having alcohol once a month at baseline, 6 percent at the third visit, and 4 
percent at the fifth visit. The proportion of alcohol users is lower among participants in the case 
management arm than in those in the standard care arm. In addition, the proportion of alcohol 
users was higher on the third visit than in other visits.
Most CM participants surveyed in this study reported drinking up to three or four glasses of 
alcohol a day (44%) at the fifth visit. Those who consume one to two drinks per day represent 44 
percent of this population. Those who have seven to nine drinks a day account for 11 percent.
The proportion of people in the SOC arm who have more than six drinks per day was not 
negligible, but there was a downward trend with progressive visits: 7 percent at baseline, 6 
percent at the third visit, and 5.6 percent at the fifth visit. The proportion of people reporting drug 
injection in the last 3 months prior to the surveys was very low: 0.7 percent of SOC respondents 
at baseline, 0 percent at the third visit, and 2 percent at the fifth visit.
Antiretroviral therapy
Table 12 displays characteristics of ART medication including the percentage of participants 
initiating ART in the past 30 days, the ability to take ART medication, frequency of appropriate ART 
drug administration, and present use of medication. 
The proportion of participants in the SOC arm who reported a very poor ability to take ART 
medication between the third and fifth visits increased from 0.6 percent to 3 percent. Those with 
a very good ability to take ART medication increased from 31 percent to 37 percent, and those 
with an excellent ability increased from 26 percent to 29 percent. In the CM arm, there was an 
increase from 1 percent to 2 percent in participants who reported a very poor ability to take ART 
medication. Participants with a good ability increased from 26 percent to 27 percent, and those 
with an excellent ability similarly decreased from 36 percent during the third visit to 29 percent 
during the fifth visit.
Participants were also asked to indicate how often ART medication was taken as required. At 
the third visit in the SOC group, 1 percent reported they never did, which increased to 2 percent 
at the fifth visit. Between the third and fifth visit there was a decrease from 16 percent to 1 
percent in those who often took their ART medication when they were supposed to. There was 
a large increase among those who always took their ART medication when required, from 0.6 
percent to 74 percent between third and fifth visits. Among the CM group, there was a reported 
increase from 3 percent to 4 percent in those who never took their medication. A decrease from 
9 percent to 2 percent was displayed in those who often took their medication, and an increase 
from 0 percent to 73 percent in those who always displayed appropriately timed usage of ART 
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medication.
During both the third and fifth visits, 98 percent of participants in the SOC reported currently 
taking their ART medication. Similarly, in the CM group, 99 percent of participants reported 
current usage at the third visit; however, this percentage decreased to 98 percent during the fifth 
visit. 
ART medication stockouts
Participants were asked to answer questions related to ART drugs stock outs at health facilities. 
In the SOC group, 20 percent reported that a health facility did not have the required ART drugs 
available since the time of study enrollment. Similarly, 24 percent reported a lack of ART drugs 
Table 11  Substance use among participants in study arms—12-month follow up














n (%) n (%) n (%) n (%) n (%) n (%)
Alcohol consumption in 
last 3 months
Never 252 (90) 277 (95) 145 (89) 152 (92) 156 (90) 159 (95)
1 per month or less 14 (5) 7 (2) 9 (6) 8 (5) 7 (4) 6 (4)
2–4 per month 5 (2) 3 (1) 3 (2) 3 (2) 5 (3) 1 (0.6)
2–3 per week 2 (0.7) 4 (1) 2 (1) 1 (0.6) 2 (1) 0 (0)
4 > per week 7 (3) 1 (0.3) 3 (2) 1 (0.6) 4 (2) 2 (1)
Refusal 1 (0.4) 0 (0) 0.076 1 (0.6) 0 (0) 0.770 156 (90) 159 (95) 0.255
Standard glasses per 
day
1–2 17 (61) 9 (60) 7 (41) 7 (54) 7 (39) 4 (44)
3–4 5 (18) 4 (27) 7 (41) 2 (15) 8 (44) 4 (44)
5–6 1 (4) 1 (7) 1 (6) 1 (8) 1 (6) 0 (0)
7–9 2 (7) 1 (7) 1 (6) 1 (8) 1 (6) 1 (11)
10 or more 2 (7) 0 (0) 1 (6) 1 (8) 1 (6) 0 (0)
Don’t know 1 (4) 0 (0) 0.825 0 (0) 1 (8) 0.653 7 (39) 4 (44) 0.862
6 standard glasses or 
more at a time
Never 7 (25) 5 (33) 13 (77) 5 (39) 6 (33) 5 (56)
Less than once per 
month
8 (29) 4 (27) 1 (6) 1 (8) 6 (33) 1 (11)
Once per month 4 (14) 2 (13) 1 (6) 2 (15) 2 (11) 1 (11)
Once per week 4 (14) 2 (13) 0 (0) 3 (23) 3 (17) 0 (0)
Every day or almost 
every day
4 (14) 2 (13) 2 (12) 1 (8) 0 (0) 2 (22)
Don’t know 1 (4) 0 (0) 0.976 0 (0) 1 (8) 0.166 1 (6) 0 (0) 0.164
Ever used injection 
drugs
2 (0.7) 1 (0.3) 0.540 0 (0) 1 (0.6) 0.320 4 (2) 3 (2) 0.738
in the CM group. Eighty percent and 75 percent did not report ART drugs stockouts at health 
facilities in the SOC and CM groups, respectively. Overall, 22 percent reported a lack of ART drugs 
at health facilities, while 78 percent did not experience a shortage of ART drugs.
The duration of stockouts was reported to be greater than two weeks among 31 percent of SOC 
participants. Twenty-nine percent of participants noted a stockout of 1–2 weeks, and 18 percent 
of participants reported a shortage that lasted 1–2 days or 3–6 days. Twenty-seven percent of 
participants in the CM arm also reported the greatest shortage of longer than two weeks, while 
29 percent reported a duration of 3–6 days. Twenty-two percent of participants noted a stock 
out of both 1–2 days and 1–2 weeks. Overall, 28 percent of participants reported a stock out of 
longer than two weeks, 25 percent of 1–2 weeks, 24 percent of 3–6 days, and 20 percent of 1–2 
days. 
Overall, 33 percent of participants were referred elsewhere for ART drugs, while 67 percent 
were not provided with a referral. Specifically, 18 percent of participants in the SOC arm and 46 
percent of participants in the CM arm were referred elsewhere.
Table 13  ART medication stockouts at health facilities
Table 12  Ability to take ART medication—12 months follow-up














n (%) n (%) n (%) n (%) n (%) n (%)
Ability to take ART 
medication
Very poor 1 (0.8) 6 (5) 1 (0.6) 2 (1) 5 (3) 4 (2)
Poor 5 (41) 1 (0.7) 1 (0.6) 0 (0) 1 (0.6) 2 (1)
Average 4 (3) 4 (3) 5 (3) 4 (3) 3 (2) 1 (0.6)
Good 42 (35) 42 (31) 52 (33) 41 (26) 49 (29) 45 (27)
Very good 37 (31) 37 (28) 59 (37) 55 (34) 64 (37) 65 (40)
Excellent 31 (26) 43 (32) 41 (26) 57 (36) 50 (29) 47 (29)
Don’t know 1 (0.8) 1 (0.7) 0.274 0 (0) 1 (0.6) 0.370 0 (0) 1 (0.6) 0.860
ART medication taken 
as supposed to
Never 5 (4) 9 (7) 2 (1) 4 (3) 4 (2) 6 (4)
Rarely 4 (3) 1 (0.7) 4 (3) 3 (2) 2 (1) 0 (0)
Sometimes 2 (2) 0 (0) 14 (9) 10 (6) 2 (1) 2 (1)
Often 9 (7) 9 (7) 25 (16) 15 (9) 2 (1) 3 (2)
Almost always 13 (11) 19 (14) 113 (71) 128 (80) 35 (20) 33 (20)
Always 88 (73) 95 (71) 1 (0.6) 0 (0) 127 (74) 121 (73)
Don’t know 0 (0) 1 (0.7) 0.350 2 (1) 4 (3) 0.315 4 (2) 6 (4) 0.752
Are you currently 
taking your HIV 
medication?
117 (97) 127 (95) 0.452 157 (99) 159 (99) 0.558 170 (99) 161 (98) 0.381
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SOC (n=22) CM (n=11) Total (n=33) p-value
n (%) n (%) n (%)
ART drugs not available 
No 139 (80) 126 (75) 265 (78)
Yes 34 (20) 41 (24) 75 (22)
Refusal 0 (0) 1 (0.6) 1 (0.3)
Don’t know 1 (0.6) 0 (0) 1 (0.3) 0.364
Longest stock out (in days)
1–2 days 6 (18) 9 (22) 15 (20)
3–6 days 6 (18) 12 (29) 18 (24)
1–2 weeks 10 (29) 9 (22) 19 (25)
More than 2 weeks 10 (29) 11 (27) 21 (28)
Don’t know 2 (6) 0 (0) 2 (3) 0.395
Referred elsewhere
No 28 (82) 22 (54) 50 (67)
Yes 6 (17) 19 (46) 25 (33) 0.009
Intervention evaluation 
Participants in the SOC (n=93) and CM (n=123) arms of the intervention were read a series of 
statements regarding their interactions with the case manager over the duration of the study. 
They were then asked to rate their reaction to the statement as one of five categories: strongly 
agree, agree, neither agree nor disagree (neutral), disagree, or strongly disagree. Questions 
referenced participant experiences and acceptability regarding in person interactions with the 
case manager as well as SMS and phone contact. Table 14 presents participant answers during 
the fifth visit, 12 months after initiation of the intervention.
When read the statement “I was satisfied with the case manager,” 33 percent of SOC participants 
responded that they strongly agreed and 60 percent that they agreed. In the CM group the 
numbers were 30 percent and 65 percent, respectively. Ninety-five percent of SOC participants 
indicated that they either strongly agreed or agreed that they found the meetings with the case 
manager to be helpful, while 99 percent of CM participants had the same response. Additionally, 
96 percent of SOC respondents indicated that they strongly agreed or agreed with the statement 
“I felt comfortable with my case manager,” compared to 91 percent for the CM arm. Nineteen 
percent of the SOC arm and 15 percent of the CM arm responded that they agreed or strongly 
agreed with the statement “I don’t find the meetings with the case manager to be important;” the 
percentage of those that strongly agreed was 5 percent in the SOC arm and 7 percent in the CM 
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group.
In both groups, most participants either disagreed or strongly disagreed with the statement “I 
don’t think these meetings with my case manager had an impact on achieving my treatment 
objectives.” Thirty-three percent of the SOC group and 28 percent of the CM group strongly 
disagreed with the statement, and 42 percent and 58 percent disagreed, respectively. Nineteen 
percent of the SOC group felt that they could not express themselves freely during meetings with 
their case manager, while 11 percent of CM participants responded in the same way. 
Among the SOC arm respondents, 38 percent strongly agreed and 56 percent agreed that the 
meetings were presented in a way that made them sound interesting, while 37 percent and 
59 percent of CM participants had the same answers, respectively. Ninety-five percent of SOC 
participants either agreed or strongly agreed that the case manager was knowledgeable about 
the topics discussed, and 96 percent of CM participants responded positively to this question. 
In both groups, a large majority agreed that the case manager had tried to understand their 
individual needs.
Participants were also read the statement “certain topics that I discussed with the case manager 
made me uncomfortable.” Eighty-nine percent of the CM group and 90 percent of the SOC group 
either disagreed or strongly disagreed. Meanwhile, 5 percent of the CM group responded that 
they neither agreed not disagreed, and 5 percent agreed or strongly agreed. Among the SOC 
group, 5 percent either agreed or strongly agreed, and no respondents responded neutrally. 
In both treatment groups no participants indicated that the case manager was not respectful of 
their choices, although 0.8 percent of the CM respondents indicated that they neither agreed 
nor disagreed with the statement. A majority of respondents in both groups (91%) said that they 
planned to attend future meetings with their case manager, representing 88 percent of SOC 
participants and 94 percent of CM participants.  
Participants were also asked to respond to a number of questions regarding the feasibility and 
acceptability of implementing the proposed strategies. Thirty-nine percent of SOC respondents 
believed they had enough money to implement the proposed strategies (20% strongly agreed and 
18% agreed), while 28 percent believed they do not (20% disagreed and 8% strongly disagreed). 
In the CM arm, meanwhile, 50 percent of respondents believed they have enough money (19% 
strongly agreed and 32% agreed), and 32 percent believed they do not (23% disagreed and 9% 
strongly disagreed). Similarly, participants were asked whether they believed they have the tools 
needed to implement the proposed strategies. Sixty-nine percent of SOC respondents believed 
they did (28% strongly agreed and 41% agreed), while 78 percent of CM participants responded 
positively (28% strongly agreed and 50% agreed). In both groups, a vast majority indicated that 
they either strongly agreed or agreed that they felt better equipped after the intervention (95% in 
the SOC group and 98% in the CM group).
In regard to expanding the program to all PLHIV, 95 percent of the SOC group and 98 percent 
of the CM group either strongly agreed or agreed that meetings with a case manager should be 
made available to all PLHIV. The percentage that either disagreed or strongly disagreed with the 
statement was 2 percent in both the SOC group and the CM group. Participants were also asked 
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whether they planned to share what they had learned in the meetings with other PLHIV. Ninety-
five percent of the SOC group replied positively (45% strongly agreed and 50% agreed). The 
CM group also had a high positive response rate of 98 percent (42% strongly agreed and 55% 
agreed).
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n (%) n (%) n (%)
I was satisfied with the case manager     
 Strongly disagree 1 (1) 2 (2) 3 (1)  
 Disagree 1 (1) 0 (0) 1 (0.5)  
 Neutral 2 (2) 3 (2) 5 (2)  
 Agree 56 (60) 80 (65) 136 (63)  
 Strongly agree 31 (33) 37 (30) 68 (32)  
 Refusal 0 (0) 1 (0.8) 1 (0.5)  
 Don't know 2 (2) 0 (0) 2 (0.9) 0.514
I thought the meetings with the case manager took too long     
 Strongly disagree 29 (31) 33 (27) 62 (29)  
 Disagree 30 (32) 46 (37) 76 (35)  
 Neutral 1 (1) 4 (3) 5 (2)  
 Agree 18 (19) 22 (18) 40 (19)  
 Strongly agree 13 (14) 16 (13) 29 (13)  
 Refusal 0 (0) 1 (0.8) 1 (0.5)  
 Don't know 2 (2) 1 (0.8) 3 (1) 0.761
I found the meeting with the case manager to be helpful     
 Strongly disagree 1 (1) 0 (0) 1 (0.5)  
 Disagree 2 (2) 0 (0) 2 (0.9)  
 Neutral 1 (1) 0 (0) 1 (0.5)  
 Agree 49 (53) 72 (59) 121 (56)  
 Strongly agree 39 (42) 50 (41) 89 (41)  
 Don't know 1 (1) 1 (0.8) 2 (0.9) 0.339
I felt comfortable with my case manager     
 Disagree 1 (1) 1 (0.8) 2 (0.9)  
 Neutral 1 (1) 1 (0.8) 2 (0.9)  
 Agree 53 (57) 74 (60) 127 (59)  
 Strongly agree 36 (39) 47 (38) 83 (38)  
 Don't know 2 (2) 0 (0) 2 (0.9) 0.589
The strategies proposed by the case manager helped me be more observant of my 
treatment     
 Neutral 0 (0) 1 (50) 1 (33)  
 Agree 1 (100) 1 (50) 2 (67) 0.386
The discussion helped me accept that I am living with HIV     
 Disagree 2 (2) 0 (0) 2 (0.9)  
 Neutral 2 (2) 0 (0) 2 (0.9)  
 Agree 54 (58) 74 (60) 128 (59)  
 Strongly agree 34 (37) 48 (39) 82 (38)  
 Refusal 0 (0) 1 (0.8) 1 (0.5)  
 Don't know 1 (1) 0 (0) 1 (0.5) 0.186
I don't find the meetings with the case manager to be important     
 Strongly disagree 32 (34.4) 39 (32) 71 (33)  
 Disagree 39 (41.9) 61 (50) 100 (46)  
 Neutral 2 (2.2) 2 (2) 4 (2)  
 Agree 13 (14.0) 10 (8) 23 (11)  
 Strongly agree 5 (5.4) 9 (7) 14 (7)  
 Don't know 2 (2.2) 2 (2) 4 (2) 0.707
I believe I have enough money to implement the proposed strategies     
 Strongly disagree 7 (7.5) 11 (9) 18 (8)  
 Disagree 19 (20.4) 28 (23) 47 (22)  
 Neutral 27 (29.0) 19 (15) 46 (21)  
 Agree 17 (18.3) 39 (32) 56 (26)  
 Strongly agree 19 (20.4) 23 (19) 42 (19)  
 Refusal 1 (1) 1 (0.8) 2 (0.9)  
 Don't know 3 (3) 2 (2) 5 (2) 0.161
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I believe I have the tools I need to implement the proposed strategies     
 Strongly disagree 1 (1) 4 (3) 5 (2)  
 Disagree 7 (8) 5 (4) 12 (6)  
 Neutral 17 (18) 16 (13) 33 (15)  
 Agree 38 (41) 62 (50) 100 (46)  
 Strongly agree 26 (28) 34 (28) 60 (28)  
 Don't know 4 (4) 2 (2) 6 (3) 0.347
I think the location of these meetings with the case manager is too far away from where 
I live     
 Strongly disagree 23 (25) 30 (24) 53 (25)  
 Disagree 40 (43) 57 (46) 97 (45)  
 Neutral 2 (2) 3 (2) 5 (2)  
 Agree 18 (19) 25 (20) 43 (20)  
 Strongly agree 9 (10) 7 (6) 16 (7)  
 Don't know 1 (1) 1 (0.8) 2 (0.9) 0.929
I don't think these meetings with my case manager had an impact on achieving my 
treatment objectives     
 Strongly disagree 31 (33) 34 (28) 65 (30)  
 Disagree 39 (42) 71 (58) 110 (51)  
 Neutral 2 (2) 2 (2) 4 (2)  
 Agree 10 (11) 9 (7) 19 (9)  
 Strongly agree 8 (9) 5 (4) 13 (6)  
 Don't know 3 (3) 2 (2) 5 (2) 0.274
I sometimes felt that I could not express myself freely during these meetings     
 Strongly disagree 29 (31) 39 (32) 68 (32)  
 Disagree 44 (47) 60 (49) 104 (48)  
 Neutral 1 (1) 2 (2) 3 (1)  
 Agree 12 (13) 15 (12) 27 (13)  
 Strongly agree 3 (3) 5 (4) 8 (4)  
 Refusal 0 (0) 1 (0.8) 1 (0.5)  
 Don't know 4 (4) 1 (0.8) 5 (2) 0.703
I plan on attending future meetings with my case manager     
 Strongly disagree 1 (1) 2 (2) 3 (1)  
 Disagree 5 (5) 2 (2) 7 (3)  
 Neutral 3 (3) 3 (2) 6 (3)  
 Agree 48 (52) 77 (63) 125 (58)  
 Strongly agree 33 (36) 38 (31) 71 (33)  
 Don't know 3 (3) 1 (0.8) 4 (2) 0.343
The meetings were presented in a way that made them sound interesting     
 Disagree 0 (0) 2 (2) 2 (0.9)  
 Neutral 3 (3) 1 (0.8) 4 (2)  
 Agree 52 (56) 73 (59) 125 (58)  
 Strongly agree 35 (38) 45 (37) 80 (37)  
 Don't know 3 (3) 2 (2) 5 (2) 0.422
These meetings with a case manager should be made available to all PLHIV     
 Strongly disagree 2 (2) 1 (0.8) 3 (1)  
 Disagree 0 (0) 1 (0.8) 1 (0.5)  
 Neutral 2 (2) 1 (0.8) 3 (1)  
 Agree 46 (50) 68 (55) 114 (53)  
 Strongly agree 42 (45) 52 (42) 94 (44)  
 Don't know 1 (1) 0 (0) 1 (0.5) 0.566
I plan on sharing what I've learned in the meetings with other PLHIV     
 Strongly disagree 4 (4) 5 (4) 9 (4)  
 Disagree 3 (3) 17 (14) 20 (9)  
 Neutral 1 (1) 2 (2) 3 (1)  
 Agree 51 (55) 55 (45) 106 (49)  
 Strongly agree 33 (36) 39 (32) 72 (33)  
 Don't know 1 (1) 5 (4) 6 (3) 0.088
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The case manager was knowledgeable about the topics we discussed     
 Strongly disagree 0 (0) 1 (0.8) 1 (0.5)  
 Neutral 0 (0) 1 (0.8) 1 (0.5)  
 Agree 52 (56) 75 (61) 127 (59)  
 Strongly agree 36 (39) 43 (35) 79 (37)  
 Don't know 5 (5) 3 (2) 8 (4) 0.528
The case manager tried to understand my individuals needs     
 Strongly disagree 1 (1) 0 (0) 1 (0.5)  
 Disagree 0 (0) 1 (0.8) 1 (0.5)  
 Neutral 1 (1) 1 (0.8) 2 (0.9)  
 Agree 50 (54) 77 (63) 127 (59)  
 Strongly agree 40 (43) 42 (34) 82 (38)  
 Don't know 1 (1) 2 (2) 3 (1) 0.545
The case manager was respectful of my choices     
 Neutral 0 (0) 1 (0.8) 1 (0.5)  
 Agree 52 (56) 71 (58) 123 (57)  
 Strongly agree 40 (43) 51 (42) 91 (42)  
 Don't know 1 (1) 0 (0) 1 (0.5) 0.544
The case manager took my situation into account when proposing strategies     
 Agree 14 (56) 27 (61) 41 (59)  
 Strongly agree 11 (44) 17 (39) 28 (41) 0.663
The case manager referred me to the appropriate services     
 Disagree 0 (0) 1 (8) 1 (7)  
 Neutral 0 (0) 1 (8) 1 (7)  
 Agree 1 (100) 8 (62) 9 (64)  
 Strongly agree 0 (0) 3 (23) 3 (21) 0.897
I feel better equipped     
 Disagree 2 (2) 0 (0) 2 (0.9)  
 Neutral 1 (1) 2 (2) 3 (1)  
 Agree 51 (55) 75 (61) 126 (58)  
 Strongly agree 37 (40) 45 (37) 82 (38)  
 Don't know 2 (2) 1 (0.8) 3 (1) 0.416
Certain topics that I discussed with the case manager made me uncomfortable     
 Strongly disagree 32 (34) 39 (32) 71 (33)  
 Disagree 52 (56) 70 (57) 122 (57)  
 Neutral 0 (0) 6 (5) 6 (3)  
 Agree 1 (1) 5 (4) 6 (3)  
 Strongly agree 4 (4) 1 (0.8) 5 (2)  
 Don't know 4 (4) 2 (2) 6 (3) 0.062
Overall, how would you rate your meetings with a case manager?     
 Very poor 0 (0) 1 (0.8) 1 (0.5)  
 Poor 0 (0) 1 (0.8) 1 (0.5)  
 Average 3 (3) 4 (3) 7 (3)  
 Good 52 (56) 59 (48) 111 (51)  
 Very good 36 (39) 57 (46) 93 (43)  
 Don't know 2 (2) 1 (0.8) 3 (1) 0.614
How easy or difficult was it for you to come here today?     
 Not difficult at all 81 (87.) 106 (86) 187 (87)  
 Somewhat difficult 7 (8) 11 (9) 18 (8)  
 Very difficult 2 (2) 2 (2) 4 (2)  
 Extremely difficult 3 (3) 1 (0.8) 4 (2)  
 Don't know 0 (0) 3 (2) 3 (1) 0.387
Intervention sustainability
Reminding patients to take ART medication over the phone is often considered essential for 
patient adherence to treatment. In this study, almost all respondents in both arms reported they 
would continue taking ART medication without telephone reminders. Indeed, 46 percent of the 
SOC arm participants and 39 percent of those in the CM arm strongly agreed that they could do 
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so. Similarly, 50 percent of SOC participants and 57 percent in the CM arm agreed. Additionally, 
95 percent of participants in SOC and 96 percent of those in CM believed they would adhere to 
treatment without case managers' intervention.
In contrast to those who reported taking ART medication without the intervention of case 
managers, a significant proportion of participants surveyed in both arms of the study appeared to 
still need the help of case managers to deal with other health-related problems. Indeed, 5 percent 
of SOC participants and 3 percent in CM disagreed or strongly disagreed that they could continue 
to manage their health problems independently. 
Several participants in both arms of the study still felt they needed case managers' support to 
face daily health challenges. Eight percent of SOC participants and 5 percent of those in CM 
reported they could not overcome these challenges without the case managers' help. Eighty-three 
percent of SOC participants and 91 percent in CM would continue receiving support from the 
case manager if available. 
Sixty-one percent of participants in both arms said they never stopped taking ART medication 
because of life events they were involved in during the study period, representing 59 percent of 
SOC participants and 64 percent of CM. 
Sixty-one percent of participants in CM and 60 percent in SOC at the fifth visit reported continuing 
their ART therapy despite having difficulties attending their follow-up appointment. Over half of 
the participants in both arms of the study, 58 percent of participants in CM and 53 percent of 
participants in SOC, reported continuing treatment despite not seeing any improvement in their 
health. 
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n (%) n (%) n (%)
Able to continue to take ART medication without regular calls from case manager
Strongly disagree 3 (2) 5 (3) 8 (2)
Disagree 1 (0.6) 0 (0) 1 (0.3)
Neutral 2 (1) 0 (0) 2 (0.6)
Agree 87 (50) 96 (57) 183 (54)
Strongly agree 80 (46) 65 (39) 145 (42)
Don’t know 1 (0.6) 2 (1) 3 (0.9) 0.334
Able to continue to take your ART medication without regular SMS from case manager
Strongly disagree 2 (1) 3 (2) 5 (2)
Disagree 2 (1) 1 (0.6) 3 (0.9)
Neutral 2 (1) 2 (1) 4 (1)
Agree 88 (51) 98 (58) 186 (54)
Strongly agree 79 (45) 63 (38) 142 (42)
Don’t know 1 (0.6) 1 (0.6) 2 (0.6) 0.735
Able to continue to take your ART medication without regular meetings with case 
manager
Strongly disagree 3 (2) 1 (0.6) 4 (1)
Disagree 1 (0.6) 1 (0.6) 2 (0.6)
Neutral 3 (2) 2 (1) 5 (2)
Agree 95 (55) 100 (60) 195 (57)
Strongly agree 70 (40) 61 (36) 131 (38)
Refusal 1 (0.6) 0 (0) 1 (0.3)
Don’t know 1 (0.6) 3 (2) 4 (1) 0.698
Capable of seeking supportive services for additional health challenges in the future
Strongly disagree 1 (0.6) 1 (0.6) 2 (0.6)
Disagree 7 (4) 4 (2) 11 (3)
Neutral 5 (3) 6 (4) 11 (3)
Agree 87 (50) 96 (57) 183 (54)
Strongly agree 61 (35) 51 (30) 112 (33)
Refusal 0 (0) 3 (2) 3 (0.9)
Don’t know 13 (8) 7 (4) 20 (6) 0.326
Capable of seeking supportive services for additional life challenges in the future
Strongly disagree 3 (2) 2 (1) 5 (2)
Disagree 11 (6) 6 (4) 17 (5)
Neutral 7 (4) 5 (3) 12 (4)
Agree 87 (50) 96 (57) 183 (54)
Strongly agree 52 (30) 49 (29) 101 (30)
Refusal 1 (0.6) 1 (0.6) 2 (0.6)
Don’t know 13 (8) 9 (5) 22 (6) 0.789
Continue with current support from case manager if available
No 19 (11) 12 (7) 31 (9)
Yes 144 (83) 152 (91) 296 (87)
Refusal 1 (0.6) 1 (0.6) 2 (0.6)
Don’t know 10 (6) 3 (2) 13 (4) 0.141
Stick to treatment plan even when side effects interfere 
Cannot do at all 13 (8) 14 (8) 27 (8)
Moderately certain can do 5 (3) 4 (2) 9 (3)
Completely certain can do 92 (53) 92 (55) 184 (54)
N/A: This has never happened to me before 64 (37) 57 (34) 121 (35)
Don’t know 0 (0) 1 (0.6) 1 (0.3) 0.836
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Integrate treatment even if in front of people
Cannot do at all 5 (3) 6 (4) 11 (3)
Moderately certain can do 6 (3) 9 (5) 15 (4)
Completely certain can do 96 (55) 96 (57) 192 (56)
N/A: This has never happened to me before 66 (38) 56 (33) 122 (36)
Refusal 1 (0.6) 0 (0) 1 (0.3)
Don’t know 0 (0) 1 (0.6) 1 (0.3) 0.638
Stick to treatment schedule when daily routine is disrupted
Cannot do at all 3 (2) 2 (1) 5 (2)
Moderately certain can do 11 (6) 7 (4) 18 (5)
Completely certain can do 102 (59) 107 (64) 209 (61)
N/A: This has never happened to me before 58 (33) 51 (30) 109 (32)
Don’t know 0 (0) 1 (0.6) 1 (0.3) 0.635
Stick to treatment schedule when not feeling well
Cannot do at all 4 (2) 1 (0.6) 5 (2)
Moderately certain can do 6 (3) 7 (4) 13 (4)
Completely certain can do 103 (59) 107 (64) 210 (61)
N/A: This has never happened to me before 61 (35) 50 (30) 111 (33)
Don’t know 0 (0) 3 (2) 3 (0.9) 0.204
Continue with treatment even if interferes with daily activities
Cannot do at all 5 (3) 1 (0.6) 6 (2)
Moderately certain can do 6 (3) 8 (5) 14 (4)
Completely certain can do 113 (65) 108 (64) 221 (65)
N/A: This has never happened to me before 50 (29) 48 (29) 98 (29)
Don’t know 0 (0) 3 (2) 3 (0.9) 0.199
Continue with treatment when feeling discouraged about health
Cannot do at all 4 (2) 1 (0.6) 5 (2)
Moderately certain can do 5 (3) 10 (6) 15 (4)
Completely certain can do 99 (57) 104 (62) 203 (59)
N/A: This has never happened to me before 66 (38) 51 (30) 117 (34)
Don’t know 0 (0) 2 (1) 2 (0.6) 0.116
Continue with treatment even when clinic appointments are a hassle
Cannot do at all 3 (2) 2 (1) 5 (2)
Moderately certain can do 5 (3) 9 (5) 14 (4)
Completely certain can do 106 (61) 101 (60) 207 (61)
N/A: This has never happened to me before 60 (35) 53 (32) 113 (33)
Refusal 0 (0) 1 (0.6) 1 (0.3)
Don’t know 0 (0) 2 (1) 2 (0.6) 0.442
Continue with treatment when people close tell you it is not doing good
Cannot do at all 2 (1) 2 (1) 4 (1)
Moderately certain can do 7 (4) 6 (4) 13 (4)
Completely certain can do 99 (57) 98 (58) 197 (58)
N/A: This has never happened to me before 64 (37) 59 (35) 123 (2)
Refusal 2 (1) 0 (0) 2 (0.6)
Don't know 0 (0) 3 (2) 3 (0.9) 0.394
Stick to your treatment if the medication does not improve health
Cannot do at all 4 (2) 1 (0.6) 5 (2)
Moderately certain can do 5 (3) 3 (2) 8 (2)
Completely certain can do 92 (53) 97 (58) 189 (55)
N/A: This has never happened to me before 69 (40) 62 (37) 131 (38)
Refusal 0 (0) 2 (1) 2 (0.6)
Don't know 4 (2) 3 (2) 7 (2) 0.435
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Effectiveness and durability of CM vs. SOC interventions focused on achieving SVS 
Five hundred seventy-eight were PLHIV were recruited into the study at baseline. Of these, 292 
(51%) were randomized into CM and 281 (49%) were randomized into SOC. Five participants from 
the baseline visit and five participants from the third visit were excluded from further analyses as 
their intervention randomization information were missing, thus the analyses were carried out as 
a modified Intention to Treat (mITT) analysis. 
Results for the mITT and per protocol analyses for the effectiveness of CM program at visits 
3 and 5 are presented in Table 16. Viral suppression did not differ significantly according to 
randomization group at visit 3 (77% in the SOC arm and 77% in the CM arm) and visit 5 (74% 
in the SOC arm and 70% in the CM arm). There was no evidence of the durability of viral load 
suppression among visit 3 respondents continuing in both arms. 




Modified intention to treat Per protocol 
SOC CM Difference in proportion 
(95% CI)
SOC CM Difference in proportion 
(95% CI)
Month 6 77% 77% -2.8% (-9.4%–8.8%) 81% 79% -2.2% (-1.1%–6.5%)
Month 12 74% 70% -4.5% (-1.4%–5.0%) 87% 84% -3.5% (-1.2–4.5%)
While no participant characteristics were statistically significantly associated with viral 
suppression in the third visit, in the fifth visit, moderate depression was negatively associated 
with viral suppression (Table 17). 
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Table 17  Participant characteristics associated with viral suppression at visit 3 and visit 5
Characteristics Visit 3 Visit 5 
OR (95% CI) p-value OR (95% CI) p-value 
Study arm 
SOC Ref Ref 0.303
CM 0.77 (0.42–1.40) 0.390 0.65 (0.29–1.47)
Age 0.99 (0.96–1.03) 0.769 1.03 (0.99–1.07) 0.106
Biological sex 
Male Ref Ref
Female 1.85 (0.51–6.67) 0.348 13.61 (2.55–72.6) 0.002
Gender Identity 
Male Ref Ref
Female 1.51 (0.33–4.06) 0.827 0.16 (0.04–0.67) 0.012
Other 3.75 (0.76–18.5) 0.104 0.44 (0.88–2.33) 0.333
Education 
Less than primary education Ref Ref
Primary education 0.93 (0.36–2.55) 0.881 0.71 (0.18–2.74) 0.621
Some/complete secondary education 1.12 (0.40–3.17) 0.826 0.99 (0.26–3.74) 0.987
Higher education 2.38 (0.57–9.98) 0.235 0.57 (0.10–3.28) 0.533
Other/refusal 2.66 (0.29–23.7) 0.380 0.10 (0.02–0.44) 0.002
Literacy 
Can’t read or write in French or Wolof Ref Ref
Can read or write in French or Wolof 1.40 (0.55–3.57) 0.477 0.77 (0.25–2.43) 0.663
Can read or write in both languages 1.03 (0.31–3.40) 0.966 3.39 (0.67–17.09) 0.139
Employment status 
Unemployed Ref Ref
Employed 0.83 (0.41–1.69) 0.612 1.76 (0.63–4.86) 0.278
Student/Retired 1.02 (0.26–4.08) 0.967 3.78 (0.51–28.2) 0.194
Marital status 
Single/never married Ref Ref
Married 1.49 (0.63–3.53) 0.359 1.34 (0.46–3.86) 0.593
Divorced/separated 2.21 (0.51–9.68) 0.289 –
Widowed 1.02 (0.28–3.63) 0.981 0.26 (0.06–1.19) 0.082
Mental health (PHQ-9)
None/minimal depression Ref Ref
Mild depression 1.41 (0.56–2.81) 0.774 0.62 (0.21–1.91) 0.413
Moderate depression — 0.05 (0.006–0.40) 0.005
Moderately severe/severe depression — —
Any social stigma 
No Ref Ref
Yes 0.77 (0.14–4.17) 0.757 0.36 (0.06–2.32) 0.283
Any healthcare stigma 
No Ref Ref
Yes 1.46 (0.50–4.24) 0.294 2.24 (0.38–13.29) 0.376
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Follow-up at visit 3 and 5
At the third visit, follow-up was 57 percent in the SOC arm and 53 percent in the CM arm, 
while at the fifth visit follow-up was 58 percent in the SOC arm and 55 percent in the CM arm. 
Associations with loss to follow-up are presented in Table 18. At the third visit, loss to follow-
up was negatively associated with literacy in French and/or Wolof, being employed, or being a 
student or retiree, while identifying as neither male nor female was positively associated with loss 
to follow-up. Similar associations were observed in the fifth study visit where having symptoms of 
moderately severe to severe depression at baseline was also found to positively associated with 
being lost to follow-up (p <0.1).
Cost effectiveness of CM approach
Cost-effectiveness analyses were not performed. Results for the mITT and per protocol analyses 
for the effectiveness of CM intervention at the third and fifth visits indicate no significant 
difference in viral suppression, thus no gain in health for the intervention group compared to the 
control group.
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Table 18  Loss to follow-up accounting for baseline characteristics
Characteristics Visit 3 Visit 5 
OR (95% CI) p-value OR (95% CI) p-value 
Study arm 
SOC Ref Ref
CM 1.16 (0.82-1.64) 0.405 1.08 (0.77-1.53) 0.642
Age 1.00 (0.98-1.01) 0.620 0.98 (0.97-1.00) 0.071
Sex at birth
Male Ref Ref
Female 0.67 (0.20-2.30) 0.529 1.75 (0.48-6.34) 0.393
Gender identity 
Male Ref Ref
Female 1.05 (0.32-3.42) 0.932 0.40 (0.11-1.40) 0.151
Other 2.08 (0.93-2.30) 0.076 2.16 (0.97-4.8) 0.059
Education 
Less than primary education Ref Ref
Primary education 1.24 (0.66-2.32) 0.502 0.99 (0.53-1.84) 0.970
Some/complete secondary education 1.48 (0.81-2.70) 0.200 1.25 (0.70-2.27) 0.452
Higher education 1.19 (0.49-2.91) 0.702 1.45 (0.62-3.39) 0.385
Other/refusal 2.05 (0.86-4.93) 0.380 1.15 (0.50-2.64) 0.737
Literacy 
Can’t read or write in French or Wolof Ref Ref
Can read or write in French or Wolof 0.55 (0.33-0.93) 0.026 0.59 (0.35-0.99) 0.046
Can read or write in both languages 0.25 (0.11-0.53) <0.001 0.37 (0.18-0.79) 0.009
Employment status 
Unemployed Ref Ref
Employed 0.57 (0.37-0.87) 0.008 0.78 (0.51-1.18) 0.235
Student/retired 0.43 (0.17-1.08) 0.073 0.33 (0.13-0.82) 0.018
Marital status 
Single/never married Ref Ref
Married 1.48 (0.89-2.48) 0.133 1.11 (0.66-1.85) 0..681
Divorced/separated 1.73 (0.81-3.70) 0.160 1.44 (0.67-3.06) 0.346
Widowed 1.73 (0.84-3.57) 0.139 1.45 (0.71-2.96) 0.312
Mental health (PHQ-9)
None/minimal depression Ref Ref
Mild depression 0.84 (0.56-1.28) 0.431 1.07 (0.70-1.60) 0.762
Moderate depression 0.76 (0.41-1.42) 0.386 0.68 (0.36-1.28) 0.231
Moderately severe/severe depression 0.64 (0.19-2.20) 0.32 (0.08-1.21) 0.093
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AIM 4: BIOMETRIC FOLLOW-UP SYSTEM
Overview
Iris scanning was used as a way to track participants and was focused on supporting evaluation 
of retention in ART. Preliminarily, the iris scanners and a laptop were placed in the study sites in 
Dakar and Ziguinchor, and all participants who initiated ART at these facilities had an iris scan 
as a means of registering into the study. It is these same facilities that are included as referral 
facilities for the HIVST.
The iris scanner was used with patients; however, the image of the iris was not stored. Rather, the 
image was converted into a 12-digit numerical code, which was stored in the electronic health 
record. The iRespond system was used for this study (http://irespond.org/). The iris scanners 
used were the BMT-20, which is a binoculars-type iris biometrics imaging device. The scanners 
were purchased through the iRespond’s partner and biometric technology manufacturer CMITech.
The iris scanner captured an image of the iris, and the iris camera then used USB 2.0 (500 
mAh) to transfer images to a laptop/tablet. It sent the photo to the software, which converted it 
to a global 12-digit numerical code and also generated a QR code. The iRespond software was 
encrypted, and no raw biometric images were stored. BitLocker full disk encryption was provided 
for protection of data on the device if it is stolen or lost. The image was converted through a 
binary template to ensure no potential for back-conversion (Figure 11). The Android tablets were 
used to scan the QR code, which then entered the 12-digit code along with the survey data.
Figure 11  Iris conversion
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Methods
The unique 12-digit numeric code generated through the iris scanner was connected to the study 
data collection platform, SurveyCTO. On at least a weekly basis, study staff ensured that these 
databases were synced across study sites to minimize potential for loss to follow-up. The survey 
and biologic data were stored separately by the study team, online, though will be linkable via the 
12-digit numeric code generated from the iris scan. The linking of these data did not happen at 
the clinic level to maximize safety and privacy of the individual.
Sample size
Sample size and all associated calculations were the same for the biometric follow-up system 
as for the CM vs. SOC portions of the study, given that this study was conducted with the same 
participants as those in the CM vs. SOC cohorts.
Participants and recruitment
The biometric follow-up system intervention was conducted with participants in the CM vs. 
SOC cohorts. Therefore, the eligibility criteria were the same for the biometric follow-up system 
intervention as the CM vs. SOC intervention, and no additional participants were included in 
biometric follow-up system intervention who were not included in the CM vs. SOC.
Inclusion criteria
 y 18 years of age or older
 y Mentally sound and capable of providing consent to participate
 y Agrees to complete HIV and syphilis testing
 y Speaks either French, Wolof, or both
 y Provided informed consent to participate in the study
 y Resident of Senegal for the past 3 months
 y Intention to live in Dakar or Ziguinchor for the next 12 months
 y Agrees to complete all required biological testing described in the consent form and receive 
results
 y Enrolled in the CM vs. SOC cohort
Exclusion criteria
 y Under 18 years of age
 y Demonstrates mental incapacity, under the influence of substances, or any other illness 
preventing comprehension of the study procedures and informed consent
 y Does not agree to complete all required biological testing described in the consent form or 
receive results
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 y Has not provided informed consent to participate in the study
 y Not enrolled in the CM vs. SOC cohort
Recruitment process
The biometric follow-up intervention was only conducted among participants in the CM vs. 
SOC cohorts. At the point of enrollment, the trained study staff used the iris scanner to scan 
the participant’s iris in order to generate the unique 12-digit numeric identification. With this, 
separate recruitment did not take place for Aim 4: Biometric follow-up system.
Consent process
Iris scanning was a mandatory component for enrollment into the study; therefore, if a participant 
did not consent to the use of iris scanning, they were not enrolled into the study. However, we 
included the alternatives section in the consent form for discussion with the participant if they 
were unable or unwilling to provide full and informed consent. This alternatives section discussed 
options for receiving care and treatment in the health facilities without participating in the study. 
If the participant opted out of participating in the study, they were referred back to the health 
facility staff and provided the opportunity to enroll in treatment, which is the standard of care for 
treatment in Senegal, and identical to the control arm of the study. This treatment included STI 
testing (HIV testing would have already been done), counseling, and treatment. If a participant 
retracted their consent after initial enrollment, they were offered standard of care treatment
Study implementation and data collection
Once enrolled into the study, study staff scanned the participant’s iris using the iris recognition. 
The iris scanner did not store the image of the iris, but rather, the image was converted into 
a 12-digit numerical code, which was stored in the data collection platform. The iris scanner 
captured an image of the iris, and the iris camera then used USB 2.0 (500 mAh) to transfer 
images to a laptop/tablet. It sent the photo to the software, which converted it to a global 12-digit 
numerical code and also generated a QR code. Android tablets were used to scan the QR code, 
which then entered the 12-didit code along with the survey data. There was also an option to 
send the code to the printer and print out the 12-digit code for the paper and lab forms.
The unique 12-digit numeric code generated through the iris scanner was connected to the study 
data collection platform, SurveyCTO. On at least a weekly basis, study staff ensured that these 
databases were synced across study sites to minimize potential for loss to follow-up. The survey 
and biologic data were stored separately by the study team, online, though will be linkable via the 
12-digit numeric code generated from the iris scanning. The linking of these data did not happen 
at the clinic level to maximize safety and privacy of the individual.
The iris was scanned at each study visit to identify the participant and link the information 
obtained from the study visit to the previous information collected.
The iris image was not be stored, the data collection forms did not record personal identifiers 
connecting study participants, and there were no codes providing a link.
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Data analysis
Implementation outcomes were used to evaluate uptake, routinization, acceptability, and long-
term feasibility. Implementation results were used to inform the potential for the scale up of the 
use of iris scanning as a biometric follow-up system in measurement of retention support for 
PLHIV.
Results
When asked whether the iris scanner worked from the first trial or after several trials, patients in 
both arms of the study at baseline (n=49), at visit 3 (n=115), and at visit 5 (n=171) were asked 
whether the scanner always worked. From the first trial it worked in more than 77 percent of 
cases, 78 percent at baseline, 81 percent at visit 3, and 80 percent at visit 5. However, in 22; 11 
and 16 percent of the cases for the CM arm, respectively at baseline, visit 3, and visit 5, it took 
several tries to make it work.
One goal of this part of the study was to determine if the use of the iris scanner made patients 
feel uncomfortable while using it. Responses obtained from patients at inclusion in visit 3 and 5 
show that more than 83 percent of the patients found it comfortable or very comfortable to use, 
with a slight difference depending on the visit.  
The current trend is toward increasing computerization of health activities to facilitate and make 
coding and monitoring more reliable. Within the framework of this study, the evaluation of the 
acceptability of using iris scanners as a strategy for identifying and monitoring HIV-positive 
patients was done at all visits. At baseline (n=49), visit 3 (n=115), and visit 5 (n=171), more 
than 90 percent of patients felt that the iris scanner was acceptable or very acceptable in their 
identification and follow-up. This rate of acceptability in identification for the CM participants was 
slightly higher at M6 (98%), then at M12 (93%) and at M0 (87%).
Patient satisfaction with the use of the iris scanner was very high. More than 90 percent of them 
reported being satisfied or very satisfied with the use of the device. Those who were very satisfied 
were more numerous at M0 (25%), than at M6 (11%) and M12 (18%).
Use of the iris scanner was never difficult according to 77 percent of SOC participants at baseline, 
97 percent at visit 3, and 94 percent at visit 5. The rare cases of difficulty were more present at 
baseline, with 7 percent of cases reporting it as very difficult or extremely difficult. 
As for acceptance to use the iris scanner in the future, only 4 percent of participants in the CM 
arm surveyed at visit 5 said they would refuse to use it. More than 94 percent agreed to use it in 
the future.
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Table 19  Iris scanning—acceptability and uptake














n (%) n (%) n (%) n (%) n (%) n (%)
Easy or difficult to use 
Not difficult at all 20 (77) 16 (70) 58 (97) 51 (93) 80 (94) 76 (88)
Somewhat difficult 4 (15) 3 (13) 2 (3) 2 (4) 5 (6) 5 (6)
Very difficult 0 (0) 1 (4) 0 (0) 0 (0) 0 (0) 4 (5)
Extremely difficult 1 (4) 1 (4) 0 (0) 2 (4) 0 (0) 0 (0)
Refusal 1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Don't know 0 (0) 2 (9) 0.491 0 (0) 0 (0) 0.327 0 (0) 1 (1) 0.165
Physically comfortable 
to use 
Very uncomfortable 0 (0) 2 (9) 0 (0) 1 (2) 0 (0) 0 (0)
Uncomfortable 1 (4) 2 (9) 1 (2) 0 (0) 0 (0) 3 (4)
Neither comfortable 
nor uncomfortable
13 (50) 13 (57) 3 (5) 1 (2) 5 (6) 3 (4)
Comfortable 11 (42) 6 (26) 48 (80) 42 (76) 57 (67) 63 (73)
Very comfortable 1 (4) 0 (0) 8 (13) 11 (20) 23 (27) 16 (19)
Refusal 0 (0) 2 (9) 0 (0) 0 (0) 0 (0) 1 (1)
Don't know 1 (4) 2 (9) 0.327 0 (0) 0 (0) 0.453 0 (0.) 0 (0) 0.195
Psychologically 
comfortable to use 
Very uncomfortable 0 (0) 1 (4) 1 (2) 1 (2) 0 (0) 1 (1)
Uncomfortable 2 (8) 2 (9) 4 (7) 1 (2) 2 (2) 4 (5)
Neither comfortable 
nor uncomfortable
1 (4) 2 (9) 39 (65) 42 (76) 4 (5) 3 (4)
Comfortable 7 (27) 13 (57) 16 (27) 11 (20) 58 (68) 54 (63)
Very comfortable 16 (62) 5 (22) 1 (2) 1 (2) 21 (25) 24 (28)
Refusal 0 (0) 1 (4) 4 (7) 1 (2) 0 (0) 1 (1)
Don't know 2 (8) 2 (9) 0.068 39 (65) 42 (76) 0.453 2 (2) 4 (5) 0.709
Satisfied with use 
Very dissatisfied 1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1)
Dissatisfied 1 (4) 2 (9) 1 (2) 0 (0) 0 (0) 3 (4)
Neither dissatisfied 
nor satisfied
15 (58) 18 (78) 2 (3) 2 (4) 2 (2) 3 (4)
Satisfied 9 (35) 3 (13) 50 (83) 47 (86) 67 (79) 65 (76)
Very satisfied 1 (4) 0 (0) 7 (12) 6 (11) 16 (19) 14 (16)
Refusal 1 (4) 2 (9) 0 (0) 0 (0) 0 (0) 0 (0)
Don’t know 15 (58) 18 (78.) 0.218 0 (0) 0 (0) 0.812 0 (0) 0 (0) 0.360
Willingness to use 
No 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (4)
Yes 24 (92) 23 
(100)
59 (98) 54 (98) 85 
(100)
81 (94)
Refusal 1 (4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Don’t know 1 (4) 0 (0) 0.398 1 (2) 1 (2) 0.950 0 (0) 2 (2) 0.078
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Table 20  Iris scanning—routinization and long-term feasibility














n (%) n (%) n (%) n (%) n (%) n (%)
Worked on first attempt 
or more than once
It worked the first 
attempt
22 (85) 16 (70) 44 (73) 49 (89) 68 (80) 68 (79)
I need to try several 
times for it to work
0 (0) 5 (22) 13 (22) 6 (11) 15 (18) 14 (16)
I tried several times 
and it never worked
4 (15) 2 (9) 3 (5) 0 (0) 2 (2) 4 (5)
Refusal 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Don’t know 0 (0) 0 (0) 0.040 0 (0) 0 (0) 0.060 0 (0) 0 (0) 0.706
To identify patients in 
healthcare settings
Very unacceptable 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Unacceptable 0 (0) 1 (4) 0 (0) 0 (0) 0 (0) 3 (4)
Neither acceptable 
nor unacceptable
1 (4) 1 (4) 3 (5) 1 (2) 3 (4) 3 (4)
Acceptable 15 (58) 14 (61) 49 (82) 45 (82) 62 (73) 64 (74)
Very acceptable 10 (39) 6 (26) 8 (13) 9 (16) 18 (21) 16 (19)
Refusal 0 (0) 1 (4) 0 (0) 0 (0) 1 (1) 0 (0)
Don’t know 0 (0) 0 (0) 0.581 0 (0) 0 (0) 0.602 1 (1) 0 (0) 0.399
To follow-up patient in 
healthcare settings
Very unacceptable 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 0 (0)
Unacceptable 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (4)
Neither acceptable 
nor unacceptable
1 (4) 1 (4) 3 (5) 1 (2) 3 (4) 3 (4)
Acceptable 15 (58) 14 (61) 50 (83) 46 (84) 64 (75) 64 (74)
Very acceptable 10 (39) 7 (30) 7 (12) 8 (15) 16 (19) 16 (19)
Don’t know 0 (0) 1 (4) 0 (0) 0 (0) 1 (1) 0 (0)
Refusal 0 (0) 0 (0) 0.709 0 (0) 0 (0) 0.601 1 (1) 0 (0) 0.417
Best way to identify and 
follow-up patients in the 
future
Iris scanning 19 (73) 13 (57) 49 (82) 34 (62) 67 (79) 64 (74)
Unique ID questions 4 (15) 7 (30) 9 (15) 18 (33) 13 (15) 21 (24)
Another way 1 (4) 1 (4) 1 (2) 2 (4) 3 (4) 1 (1)
Refusal 1 (4) 0 (0) 0 (0) 1 (2) 2 (2) 0 (0)
Don’t know 1 (4) 2 (9) 0.540 1 (2) 0 (0) 0.098 67 (79) 64 (74) 0.176
Leveraging adaptive implementation strategies to achieve universal coverage of ART in Senegal   ■  63
LIMITATIONS
IMPLEMENTATION
This study was conducted in government facilities, with case management and treatment 
provision led by government health facility staff. We consider this study design and 
implementation strategy to be a strength of the study, in that it aims to assess the potential 
effectiveness of an intervention in a manner which would best represent implementation and 
potential scale up through the existing infrastructure and led by the Ministry of Health. However, 
this strategy is subject to limited resources, including staff with high workload and limited 
availability, representing the existing infrastructure available to implement the interventions. 
Additionally, the study was subject to stock outs and shortages of viral load testing, ART, and 
laboratory equipment. Throughout the study, there were periods in which resource constraints 
and reagent availability were limited and affected the ability to offer universal viral load testing 
at each designated period. These challenges may have influenced the implementation of the 
intervention, appropriate provision of care and ART, and the measurement of outcomes. 
HIVST
Several limitations should be considered in this study. Participation in the pre- and post-
test questionnaires was voluntary and may not represent the full sample of individuals who 
participated in HIVST distribution. The results may therefore be subject to selection bias. 
Participants who received HIVST through network distribution were not captured in data collection 
and are not represented in this analysis. Disclosure of key population status as well as positive 
reactivity from the HIVST were low in self-reported measures of this study. The distribution 
strategy prioritized members of key populations and worked closely with existing programs 
providing services to these populations. However, only one-third of the study sample self-reported 
key population status. Therefore, it may be that HIVST reached individuals who may not currently 
be at high risk of HIV, in which case there is a need to consider strategies to more effectively 
target key populations. Alternatively, key population status may have been underreported, 
in which case HIVST was able to reach individuals unwilling to disclose their key population-
related behavior and less integrated into the key population networks. Additionally, there was a 
discrepancy between the proportion of reactive HIVST collected at the distribution sites and those 
who self-reported reactive results during post-test questionnaire. Although these figures cannot 
be linked or compared directly, it may suggest either underreporting of reactive test results, or 
possibly greater loss to follow-up for post-test questionnaires among individuals with a reactive 
HIVST.
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CONCLUSION
This study was the first HIVST pilot study conducted in Senegal describing HIVST acceptability 
and feasibility for HIV testing in the most at-risk populations. HIVST is a complementary approach 
to current testing strategies, particularly with the most at-risk populations. Self-testing can 
potentially overcome barriers to HIV testing uptake by placing the locus of control on testing on 
the individual, increasing confidentiality, and allowing members of stigmatized groups to test in 
settings of privacy, safety, and with dignity. The study was successful in reaching first-time testers, 
including a large proportion of men, young people, and people who did not traditionally access 
HIV services. 
Sustained collaboration with government and stakeholders is needed to facilitate self-test 
implementation, scale-up, and linkages to care in Senegal. The distribution of the self-test kits 
relied heavily on existing sites and networks. These results have made it possible to define 
strategies for distributing HIVST to the populations most affected by HIV for various projects 
currently being implemented in Senegal and West Africa.
CM approaches build on cognitive behavioral theory and help address barriers to treatment 
uptake, adherence, and retention. The intervention, through capacity building of case managers, 
aimed to improve patients' adherence to treatment, and hence viral load results. Case managers 
provided personalized support for health care services navigation, engagement in care, and 
treatment adherence. Although the study did not find a significant difference in the viral load 
results between the two arms at the end of the study, an improvement in viral load results was 
observed over time. Further analyses will be conducted to elucidate the factors associated with 
these outcomes.
Most participants reported being satisfied with their sessions. After the 12-month follow-up, 
participants stated that the meetings impacted the achievement of their treatment goals and 
that they felt better equipped. It should be noted that a team of health professionals supported 
the case managers on each site. Proper integration of case managers and enhancement of their 
role in the structure benefits both healthcare providers and patients. The role of case managers 
remains essential in the follow-up and retention in care of PLHIV.
The use of UIC for measuring patient retention remains essential in the context of HIV programs. 
Biometric follow-up systems such as fingerprints and the iris scanner represent an alternative to 
traditional follow-up systems. These are easy to use and offer an additional level of privacy, and 
the likelihood of duplicates is relatively low. 
The iris scanner was introduced as a tool to measure participants' retention in the study. 
Participants declared the technology easy to use and acceptable for identifying and monitoring 
patients. They also reported it as the preferred method for generating a UIC. The iris scanner thus 
represents an alternative strategy in a context where key populations are hidden and mobile, 
allowing for better monitoring and also avoiding duplication of codes. 
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RECOMMENDATIONS
 y The results from the study demonstrate that HIVST provides a complementary approach to 
reach populations who may face barriers to engagement with existing and routine HIV testing 
services. Primarily, this includes key populations and first-time testers. The study also highlights 
the importance of leveraging existing venues and networks for the distribution of HIVST 
kits. Sustained engagement with government and stakeholders is needed to facilitate the 
implementation and scale-up of HIVST and subsequent linkage to care in Senegal. Preliminary 
results from this study guided the development of national HIVST guidelines. Senegal has 
moved forward with recommending it as an additional approach to testing priority populations, 
including key populations, based on the study's preliminary results. 
 y Among participants with a reactive HIVST, 58 percent went for confirmatory testing, and among 
those with an invalid test result, none went for follow-up testing. Follow-up in this context is a 
challenge. Implementation of HIVST should include specific strategies for confirmatory testing, 
thus ensuring effective linkage to care for newly HIV diagnosed individuals.
 y  Patient monitoring in Senegal remains a challenge for the national ART program, especially 
during the agricultural season with patients absent over a long period. Study participant follow-
up was equally impacted, with participants not attending all study visits. Specific strategies 
to overcome this barrier could include strengthening of regional and cross-border referral and 
counter-referral systems between health facilities.
 y The intervention aimed to improve PLHIV's adherence to treatment by building the capacity of 
case managers and providing them with appropriate tools to facilitate support. Case managers 
appreciated the additional trainings and new strategies to improve the health of their peers. 
Study participants also expressed satisfaction with the case managers' skills, which significantly 
improved the quality of the interventions. Therefore, a continued strengthening of the case 
managers' capacity is recommended, with an emphasis on support, therapeutic education of 
the patient, and provision of adequate tools. In the absence of a close psychological follow-up, 
the case manager may provide psychological and moral support. 
 y The integration of case managers and a revaluation of their role in the structure benefit both 
health care providers and patients. On some sites, their role went beyond merely providing 
support to their peers living with HIV. They also assisted health care providers in providing 
primary care to other patients. Having case managers taking care of different categories of 
patients helps with confidentiality for PLHIV.
 y The iris scanner is an acceptable biometric technology for monitoring PLHIV. Most study 
participants found it easy and comfortable to use. The use of the scanner still requires the 
installation of additional devices, including a computer and a tablet, as well as a stable internet 
connection. Thus, field staff must receive adequate training on its use and maintenance to 
minimize interruptions and other technical difficulties that may impact visits negatively. Also, 
designing culturally appropriate messages can increase the uptake of the scanner and reassure 
patients. 
 y Regular patient follow-up was challenging at different times of the study. As an example, in 
Ziguinchor, several participants missed study visits, as they were traveling to villages away 
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from health centers and often returning for their visits at the end of the agricultural season 
(which lasts between four and five months). This seasonal migration illustrates the importance 
of having advanced strategies for improving access to health care in rural areas. This issue 
is not specific to the study, and it impacts the national health system, causing many patients 
to drop out of care and treatment. In Senegal, national directives recommend the delivery 
of doses covering a period of up to three months in the event of a prolonged absence. Thus, 
the plan developed by the case manager could include telephone calls for a closer follow-up 
of the individual's state of health and treatment adherence. Establishing adherence clubs in 
remote areas could improve support and medication intake. A one-stop-shop model, with the 
provision of various health care services, including HIV care, could also be established. Finally, 
promoting and strengthening regional and cross-border referral and counter-referral systems 
between health facilities could facilitate access to care. All these strategies must consider the 
confidentiality of patients living with HIV.
 y Some participants reported having felt different forms of stigma from the community and 
uniformed officers because of their sexual practices. However, they reported less stigma from 
health professionals. Numerous interventions were carried out within health centers before the 
study to facilitate access to care for PLHIV, particularly key populations. Community and police-
level interventions remain necessary to reduce stigma. Communication strategies addressing 
HIV-related stigma, specifically through renewed investments in advocacy campaigns targeting 
opinion leaders, including the media and religious leaders, are needed to act on the social 
environment.
 y Most study participants reported having felt no stigma in healthcare settings. The MOH 
implemented various trainings on treatment and care of PLHIV, including specifically for key 
populations. In comparison to earlier studies on these same sites, this may suggest a decrease 
of stigma in these settings, but it requires in-depth analysis to study the underlying factors 
impacting the indicators of stigma. 
 y Throughout the study, sites experienced stockouts of ART medication and viral load reagents, 
causing delays in treatment initiation and interruption and thus affecting the participants' 
health outcomes. Consequently, participants were referred to other health structures. This 
component should be evaluated before any implementation of a Test and Start strategy.
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